

## PATENT COOPERATION TREATY

PCT

## NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Assistant Commissioner for Patents  
United States Patent and Trademark  
Office  
Box PCT  
Washington, D.C. 20231  
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

<b>Date of mailing</b> (day/month/year) 15 March 2000 (15.03.00)	
<b>International application No.</b> PCT/EP99/05297	<b>Applicant's or agent's file reference</b> C 2098 PCT
<b>International filing date</b> (day/month/year) 23 July 1999 (23.07.99)	<b>Priority date</b> (day/month/year) 24 July 1998 (24.07.98)
<b>Applicant</b> SPIESS, Joachim et al	

## 1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:

14 February 2000 (14.02.00)

☐ in a notice effecting later election filed with the International Bureau on:
2. The election ☒ was
☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO  
34, chemin des Colombettes  
1211 Geneva 20, Switzerland

Facsimile No.: (41-22) 740.14.35

Authorized officer

Nestor Santesso

Telephone No.: (41-22) 338.83.38

# PCT

## REQUEST

The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty.

For receiving Office use only

International Application No.

International Filing Date

Name of receiving Office and "PCT International Application"

Applicant's or agent's file reference (if desired) (12 characters maximum) C 2098 PCT

**Box No. I TITLE OF INVENTION**  
Antagonists specific for the corticotropin-releasing factor receptor type 2 (CRFR2)

**Box No. II APPLICANT**

Name and address: (Family name followed by given name; for a legal entity full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V.  
Berlin  
DE

☐ This person is also inventor.

Telephone No.

Facsimile No.

Teleprinter No.

State (that is, country) of nationality:  
DE

State (that is, country) of residence:  
DE

This person is applicant for the purposes of:

☐ all designated States

☒ all designated States except the United States of America

☐ the United States of America only

☐ the States indicated in the Supplemental Box

**Box No. III FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S)**

Name and address: (Family name followed by given name; for a legal entity full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

SPIESS, Joachim Dr. Dr.  
Max-Planck-Institut für Experimentelle Medizin  
Hermann-Rein-Strasse 3  
37075 Göttingen  
DE

This person is:

☐ applicant only

☒ applicant and inventor

☐ inventor only (If this check-box is marked, do not fill in below.)

State (that is, country) of nationality:  
DE

State (that is, country) of residence:  
DE

This person is applicant for the purposes of:

☐ all designated States

☐ all designated States except the United States of America

☒ the United States of America only

☐ the States indicated in the Supplemental Box

☒ Further applicants and/or (further) inventors are indicated on a continuation sheet.

**Box No. IV AGENT OR COMMON REPRESENTATIVE; OR ADDRESS FOR CORRESPONDENCE**

The person identified below is hereby/has been appointed to act on behalf of the applicant(s) before the competent International Authorities as:

Name and address: (Family name followed by given name; for a legal entity full official designation. The address must include postal code and name of country.)

☒ agent

☐ common representative

Vossius & Partner  
Postfach 86 07 67  
81634 München  
DE

Telephone No.

089-4 13 04-0

Facsimile No.

089-4 13 04-111

Teleprinter No.

☐ Address for correspondence: Mark this check-box where no agent or common representative is/has been appointed and the space above is used instead to indicate a special address to which correspondence should be sent.

Continuation of Box No. III FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S)

If none of the following sub-boxes is used, this sheet should not be included in the request.

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

RÜHMANN, Andreas Dr.  
ANSTO  
Australian Nuclear Science & Technology  
Organisation, Radiopharmaceuticals Division  
Private Mail Bag 1  
MENAI NSW 2234, AU

This person is:

- ☐ applicant only  
☒ applicant and inventor  
☐ inventor only (If this check-box is marked, do not fill in below.)

State (that is, country) of nationality:

DE

State (that is, country) of residence:

AU

This person is applicant for the purposes of:

- ☐ all designated States ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

This person is:

- ☐ applicant only  
☐ applicant and inventor  
☐ inventor only (If this check-box is marked, do not fill in below.)

State (that is, country) of nationality:

State (that is, country) of residence:

This person is applicant for the purposes of:

- ☐ all designated States ☐ all designated States except the United States of America ☐ the United States of America only ☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

This person is:

- ☐ applicant only  
☐ applicant and inventor  
☐ inventor only (If this check-box is marked, do not fill in below.)

State (that is, country) of nationality:

State (that is, country) of residence:

This person is applicant for the purposes of:

- ☐ all designated States ☐ all designated States except the United States of America ☐ the United States of America only ☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

This person is:

- ☐ applicant only  
☐ applicant and inventor  
☐ inventor only (If this check-box is marked, do not fill in below.)

State (that is, country) of nationality:

State (that is, country) of residence:

This person is applicant for the purposes of:

- ☐ all designated States ☐ all designated States except the United States of America ☐ the United States of America only ☐ the States indicated in the Supplemental Box

☐ Further applicants and/or (further) inventors are indicated on another continuation sheet.

Box No. V DESIGNATION OF STATES

The following designations are hereby made under Rule 4.9(a) (mark the applicable check-boxes; at least one must be marked):

Regional Patent

- ☐ AP ARIPO Patent: CH Ghana, GM Gambia, KE Kenya, LS Lesotho, MW Malawi, SD Sudan, SZ Swaziland, UG Uganda, ZW Zimbabwe, and any other State which is a Contracting State of the Harare Protocol and of the PCT
- ☐ EA Eurasian Patent: AM Armenia, AZ Azerbaijan, BY Belarus, KG Kyrgyzstan, KZ Kazakhstan, MD Republic of Moldova, RU Russian Federation, TJ Tajikistan, TM Turkmenistan, and any other State which is a Contracting State of the Eurasian Patent Convention and of the PCT
- ☒ EP European Patent: AT Austria, BE Belgium, CH and LI Switzerland and Liechtenstein, CY Cyprus, DE Germany, DK Denmark, ES Spain, FI Finland, FR France, GB United Kingdom, GR Greece, IE Ireland, IT Italy, LU Luxembourg, MC Monaco, NL Netherlands, PT Portugal, SE Sweden, and any other State which is a Contracting State of the European Patent Convention and of the PCT
- ☐ OA OAPI Patent: BF Burkina Faso, BJ Benin, CF Central African Republic, CG Congo, CI Côte d'Ivoire, CM Cameroon, GA Gabon, GN Guinea, GW Guinea-Bissau, ML Mali, MR Mauritania, NE Niger, SN Senegal, TD Chad, TG Togo, and any other State which is a member State of OAPI and a Contracting State of the PCT (if other kind of protection or treatment desired, specify on dotted line) .....


National Patent (if other kind of protection or treatment desired, specify on dotted line):

- |   |   |
|---|---|
| <input type="checkbox"/> AL Albania .....                               | <input type="checkbox"/> LS Lesotho .....                                   |
| <input type="checkbox"/> AM Armenia .....                               | <input type="checkbox"/> LT Lithuania .....                                 |
| <input type="checkbox"/> AT Austria .....                               | <input type="checkbox"/> LU Luxembourg .....                                |
| <input checked="" type="checkbox"/> AU Australia .....                  | <input type="checkbox"/> LV Latvia .....                                    |
| <input type="checkbox"/> AZ Azerbaijan .....                            | <input type="checkbox"/> MD Republic of Moldova .....                       |
| <input type="checkbox"/> BA Bosnia and Herzegovina .....                | <input type="checkbox"/> MG Madagascar .....                                |
| <input type="checkbox"/> BB Barbados .....                              | <input type="checkbox"/> MK The former Yugoslav Republic of Macedonia ..... |
| <input type="checkbox"/> BG Bulgaria .....                              | <input type="checkbox"/> MN Mongolia .....                                  |
| <input type="checkbox"/> BR Brazil .....                                | <input type="checkbox"/> MW Malawi .....                                    |
| <input type="checkbox"/> BY Belarus .....                               | <input type="checkbox"/> MX Mexico .....                                    |
| <input checked="" type="checkbox"/> CA Canada .....                     | <input type="checkbox"/> NO Norway .....                                    |
| <input type="checkbox"/> CH and LI Switzerland and Liechtenstein .....  | <input type="checkbox"/> NZ New Zealand .....                               |
| <input type="checkbox"/> CN China .....                                 | <input type="checkbox"/> PL Poland .....                                    |
| <input type="checkbox"/> CU Cuba .....                                  | <input type="checkbox"/> PT Portugal .....                                  |
| <input type="checkbox"/> CZ Czech Republic .....                        | <input type="checkbox"/> RO Romania .....                                   |
| <input type="checkbox"/> DE Germany .....                               | <input type="checkbox"/> RU Russian Federation .....                        |
| <input type="checkbox"/> DK Denmark .....                               | <input type="checkbox"/> SD Sudan .....                                     |
| <input type="checkbox"/> EE Estonia .....                               | <input type="checkbox"/> SE Sweden .....                                    |
| <input type="checkbox"/> ES Spain .....                                 | <input type="checkbox"/> SG Singapore .....                                 |
| <input type="checkbox"/> FI Finland .....                               | <input type="checkbox"/> SI Slovenia .....                                  |
| <input type="checkbox"/> GB United Kingdom .....                        | <input type="checkbox"/> SK Slovakia .....                                  |
| <input type="checkbox"/> GD Grenada .....                               | <input type="checkbox"/> SL Sierra Leone .....                              |
| <input type="checkbox"/> GE Georgia .....                               | <input type="checkbox"/> TJ Tajikistan .....                                |
| <input type="checkbox"/> GH Ghana .....                                 | <input type="checkbox"/> TM Turkmenistan .....                              |
| <input type="checkbox"/> GM Gambia .....                                | <input type="checkbox"/> TR Turkey .....                                    |
| <input type="checkbox"/> HR Croatia .....                               | <input type="checkbox"/> TT Trinidad and Tobago .....                       |
| <input type="checkbox"/> HU Hungary .....                               | <input type="checkbox"/> UA Ukraine .....                                   |
| <input type="checkbox"/> ID Indonesia .....                             | <input type="checkbox"/> UG Uganda .....                                    |
| <input type="checkbox"/> IL Israel .....                                | <input checked="" type="checkbox"/> US United States of America .....       |
| <input type="checkbox"/> IN India .....                                 | <input type="checkbox"/> UZ Uzbekistan .....                                |
| <input type="checkbox"/> IS Iceland .....                               | <input type="checkbox"/> VN Viet Nam .....                                  |
| <input checked="" type="checkbox"/> JP Japan .....                      | <input type="checkbox"/> YU Yugoslavia .....                                |
| <input type="checkbox"/> KE Kenya .....                                 | <input type="checkbox"/> ZW Zimbabwe .....                                  |
| <input type="checkbox"/> KG Kyrgyzstan .....                            |   |
| <input type="checkbox"/> KP Democratic People's Republic of Korea ..... |   |
| <input type="checkbox"/> KR Republic of Korea .....                     |   |
| <input type="checkbox"/> KZ Kazakhstan .....                            |   |
| <input type="checkbox"/> LC Saint Lucia .....                           |   |
| <input type="checkbox"/> LK Sri Lanka .....                             |   |
| <input type="checkbox"/> LR Liberia .....                               |   |

Check-boxes reserved for designating States (for the purposes of a national patent) which have become party to the PCT after issuance of this sheet:

- ☐ .....
- ☐ .....
- ☐ .....

**Precautionary Designation Statement:** In addition to the designations made above, the applicant also makes under Rule 4.9(b) all other designations which would be permitted under the PCT except any designation(s) indicated in the Supplemental Box as being excluded from the scope of this statement. The applicant declares that those additional designations are subject to confirmation and that any designation which is not confirmed before the expiration of 15 months from the priority date is to be regarded as withdrawn by the applicant at the expiration of that time limit. (Confirmation of a designation consists of the filing of a notice specifying that designation and the payment of the designation and confirmation fees. Confirmation must reach the receiving office within the 15-month time limit.)

Box No. VI PRIORITY CLAIM		<input type="checkbox"/> Further priority claims are indicated in the Supplemental Box.	
Filing date of earlier application (day/month/year)	Number of earlier application	national application: country	Where earlier application is: regional application: regional Office international application: receiving Office
item (1) (24.07.98) 24. Juli 1998	98 11 3896.9		EP
item (2)			
item (3)			
<input checked="" type="checkbox"/> The receiving Office is requested to prepare and transmit to the International Bureau a certified copy of the earlier application(s) (only if the earlier application was filed with the Office which for the purposes of the present international application is the receiving Office) identified above as item(s): <u>1</u> <i>* Where the earlier application is an ARIPO application, it is mandatory to indicate in the Supplemental Box at least one country party to the Paris Convention for the Protection of Industrial Property for which that earlier application was filed (Rule 4.10(b)(iii)). See Supplemental Box.</i>			
Box No. VII INTERNATIONAL SEARCHING AUTHORITY			
Choice of International Searching Authority (ISA) (if two or more International Searching Authorities are competent to carry out the international search, indicate the Authority chosen; the two-letter code must be used):		Request to use results of earlier search; reference to that search (if an earlier search has been carried out by or requested from the International Searching Authority):	
ISA /EPA		Date (day/month/year)	Number Country (or regional Office)
Box No. VIII CHECK LIST: LANGUAGE OF FILING			
This international application contains the following number of sheets:		This international application is accompanied by the item(s) marked below:	
request : 4		1. <input type="checkbox"/> fee calculation sheet	
description (excluding sequence listing part) : 3		2. <input type="checkbox"/> separate signed power of attorney	
claims : 4		3. <input type="checkbox"/> copy of general power of attorney; reference number, if any:	
abstract : 1		4. <input type="checkbox"/> statement explaining lack of signature	
drawings : 4		5. <input type="checkbox"/> priority document(s) identified in Box No. VI as item(s):	
sequence listing part of description : 1		6. <input type="checkbox"/> translation of international application into (language):	
Total number of sheets : 14		7. <input type="checkbox"/> separate indications concerning deposited microorganism or other biological material	
		8. <input type="checkbox"/> nucleotide and/or amino acid sequence listing in computer readable form	
		9. <input type="checkbox"/> other (specify):	
Figure of the drawings which should accompany the abstract:		Language of filing of the international application: English	
Box No. IX SIGNATURE OF APPLICANT OR AGENT			
Next to each signature, indicate the name of the person signing and the capacity in which the person signs (if such capacity is not obvious from reading the request).			
München, 23. Juli 1999			
 Dr. Renate Barth European Patent Attorney		Ba/TG/es	

For receiving Office use only	
1. Date of actual receipt of the purported international application:	2. Drawings:
3. Corrected date of actual receipt due to later but timely received papers or drawings completing the purported international application:	<input type="checkbox"/> received:
4. Date of timely receipt of the required corrections under PCT Article 11(2):	<input type="checkbox"/> not received:
5. International Searching Authority (if two or more are competent): ISA /	6. <input type="checkbox"/> Transmittal of search copy delayed until search fee is paid.


For International Bureau use only	
Date of receipt of the record copy by the International Bureau:	

# PATENT COOPERATION TREATY

## PCT

### INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference <b>C 2098 PCT</b>		<b>FOR FURTHER ACTION</b>		See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. <b>PCT/EP99/05297</b>		International filing date (day/month/year) <b>23/07/1999</b>		Priority date (day/month/year) <b>24/07/1998</b>	
International Patent Classification (IPC) or national classification and IPC <b>C07K14/435</b>					
Applicant <b>MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DES WISSENS</b>					
<p>1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of 3 sheets, including this cover sheet.</p> <p><input type="checkbox"/> This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of sheets.</p>					
<p>3. This report contains indications relating to the following items:</p> <ul style="list-style-type: none"> <li>I <input checked="" type="checkbox"/> Basis of the report</li> <li>II <input type="checkbox"/> Priority</li> <li>III <input checked="" type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicability</li> <li>IV <input type="checkbox"/> Lack of unity of invention</li> <li>V <input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</li> <li>VI <input type="checkbox"/> Certain documents cited</li> <li>VII <input checked="" type="checkbox"/> Certain defects in the international application</li> <li>VIII <input checked="" type="checkbox"/> Certain observations on the international application</li> </ul>					
Date of submission of the demand <b>14/02/2000</b>			Date of completion of this report <b>23.11.2000</b>		
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0    Tx: 523656 epmu d Fax: +49 89 2399 - 1465			Authorized officer  <b>Mennessier, T</b>  Telephone No. +49 89 2399 8687		



**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/EP99/05297

**I. Basis of the report**

1. This report has been drawn on the basis of *(substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments (Rules 70.16 and 70.17).)*

**Description, pages:**

1-31 as originally filed

**Claims, No.:**

1-33 as originally filed

**Drawings, sheets:**

1/4-4/4 as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).  
☐ the language of publication of the international application (under Rule 48.3(b)).  
☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.  
☐ filed together with the international application in computer readable form.  
☐ furnished subsequently to this Authority in written form.  
☐ furnished subsequently to this Authority in computer readable form.  
☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.  
☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:  
☐ the claims, Nos.:

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/EP99/05297

☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

*(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)*

6. Additional observations, if necessary:

**III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability**

The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

☐ the entire international application.

☒ claims Nos. 25-33.

because:

☒ the said international application, or the said claims Nos. 30, 31 (partly), 32, 33 (each claim with respect to industrial applicability) relate to the following subject-matter which does not require an international preliminary examination (*specify*):  
**see separate sheet**

☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):

☒ the claims, or said claims Nos. 25, 26, 27-33 (these latter claims partly) are so inadequately supported by the description that no meaningful opinion could be formed.

☐ no international search report has been established for the said claims Nos. .

2. A meaningful international preliminary examination report cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

☐ the written form has not been furnished or does not comply with the standard.

☐ the computer readable form has not been furnished or does not comply with the standard.

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

1. Statement:



**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/EP99/05297

Novelty (N)	Yes:	Claims	1-24 and 27-33 (see point 3.a) of the suppl. sheet)
	No:	Claims	
Inventive step (IS)	Yes:	Claims	1-24 and 27-33 (see point 3.a) of the suppl. sheet)
	No:	Claims	
Industrial applicability (IA)	Yes:	Claims	1-24 and 31 (see point 3.c)i)) of the suppl. sheet)
	No:	Claims	

2. Citations and explanations  
**see separate sheet**

**VII. Certain defects in the international application**

The following defects in the form or contents of the international application have been noted:  
**see separate sheet**

**VIII. Certain observations on the international application**

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:  
**see separate sheet**

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/EP99/05297

1. Documents cited in this report

Reference is made to the following documents which all cited in the international search report:

- # D1: *Cell and Tissue Research*, 283(1), 1995, 117-23
- # D2: *Peptides*, 6(suppl. 3), 1985, 209-13
- # D3: *Curr. Pharm. Des.*, 1(3), 1995, 305-16
- # D4: *Proceedings of the National Academy of Sciences of the United States of America*, 95(26), 1998 December 22), 15264-9

Document D4 to which the inventors contributed appears to be the non-patent literature counterpart of the present application under examination.

2. Comments with respect to item III

- a) Claims 30, 31 (insofar as it relates to "the use of claim 30"), 32 and 33 relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(i) PCT).
- b) Claims 25, 26 and 27-33, insofar as these latter claims relate to an antibody
  - (i) Antibodies to the antagonists as recited in claim 25 are only merely mentioned as being an aspect of the invention on page 9 of the description. No particular antibody is identified elsewhere in the description, which would recognize specifically an antagonist of the invention while being not or only poorly capable of binding to the native sauvagine from which the said antagonist is derived, and which would be distinguished from the prior art anti-sauvagine antibodies (see document D1, page 118, right-hand column; and document D2, pages 211 and 212).
  - (ii) Nor is any particular anti-idotypic antibody as recited in claim 26

described in the application. It has to be stressed that examples dealing with a particular antagonist are clearly inefficient at supporting claims directed to an anti-idotypic antibody directed against an antibody which is itself directed against the said antagonist. As no such anti-idotypic antibody is described, it would be simply impossible to assess whether claims relating thereto involve an inventive step.

- (iii) Therefore, the subject-matter of claims 25-26 is so inadequately supported by the description that no meaningful opinion could be formed, this conclusion extending de facto to the subject-matter of claims 27-33, insofar as it is defined with reference to any of the said antibodies.

3. Comments with respect to item V

a) Preliminary remarks

The following comments with respect to novelty, inventive step and industrial applicability are made only with regard to claim 1-24 (as a whole) and claims 27-33 (only partly, i.e., only with respect to their subject-matter which does not relate to any antibody).

b) Novelty and inventive step (Article 33(2) and 33(3) PCT)

The various aspects of the invention as defined in the afore-mentioned claims relies on the design, synthesis and characterisation by the inventors of a high-affinity mCRFR2 $\beta$ -specific peptide antagonist. The said antagonist has its amino acid sequence based on native sauvagine. It is a truncated analog thereof lacking the 10 N-terminal amino acids. Such an analog or related truncated analogs appear not to be disclosed in the state of the art.

The technical problem solved by the invention may be regarded as the development of CRFR-2 specific antagonists to (i) permit discrimination between receptor type-specific functions, (ii) serve as a useful tool to detect CRFR2 and elucidate its functional role in the brain and peripheral organs,

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/EP99/05297

and (iii) be efficient at treating a CRFR2-associated disease.

Focusing on the development of non-peptide antagonists (see D3, page 313, right-hand column) the state of the art would lead the person skilled in the art away from the solution proposed by the invention.

Therefore, it may be acknowledged that the various aspects of the invention as defined in the afore-mentioned claims are new and involve an inventive step.

c) Industrial applicability (Article 33(4) PCT)

- (i) The subject-matter of claims 1-24 and that of claim 31, insofar as it relates to *'The antagonist of any one of claims 1 to 18, or 24'*, is considered to be susceptible of industrial applicability.
- (ii) For the assessment of the present claims 30, 31 (insofar as it relates to *"the use of claim 30"*), 32 and 33 on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

d) P-document

Should the various aspects of the claimed invention appear not to be entitled to the claimed priority date, document D4 which is cited in the international search report as a P-document should be taken into consideration when examining whether the invention is new and involves an inventive step.

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/EP99/05297

4. Comments with respect to item VII

The Applicants are advised that some national/regional patent offices such as the EPO would object to a claim which as present claim 31 is directed to more than one object, the claimed objects being of different categories.

5. Comments with respect to item VIII

- a) As it has not been explicitly specified in claim 1 that the amino acid sequence of the antagonist is based on sauvagine the claimed subject-matter is considered not to be unambiguously defined. Claim 1 is therefore objected to under Article 6 PCT.
- b) In view of the comments made at point 3 above, claims 25 to 33 are objected to under Article 6 PCT.

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>C07K 14/435, 16/18, A61K 38/16, 39/395, C12N 15/12, 15/63, G01N 33/53, 33/68 // C07K 105:00</b>	<b>A3</b>	<b>(11) International Publication Number:</b> <b>WO 00/05253</b> <b>(43) International Publication Date:</b> 3 February 2000 (03.02.00)
<b>(21) International Application Number:</b> PCT/EP99/05297 <b>(22) International Filing Date:</b> 23 July 1999 (23.07.99)  <b>(30) Priority Data:</b> 98113896.9 24 July 1998 (24.07.98) EP  <b>(71) Applicant (for all designated States except US):</b> MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. [DE/DE]; Berlin (DE).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> SPIESS, Joachim [DE/DE]; Max-Planck-Institut für Experimentelle Medizin, Hermann-Rein-Strasse 3, D-37075 Göttingen (DE). RÜHMANN, Andreas [DE/AU]; ANSTO, Australian Nuclear Science & Technology Organisation, Radiopharmaceuticals Division, Private Mail Bag 1, Menai, NSW 2234 (AU).  <b>(74) Agent:</b> VOSSIUS & PARTNER; Postfach 86 07 67, D-81634 München (DE).		<b>(81) Designated States:</b> AU, CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i>  <b>(88) Date of publication of the international search report:</b> 15 June 2000 (15.06.00)
<b>(54) Title:</b> ANTAGONISTS SPECIFIC FOR THE CORTICOTROPIN-RELEASING FACTOR RECEPTOR TYPE 2 (CRFR2)		
<b>(57) Abstract</b> <p>The present invention relates to an antagonist of the ligand of the Corticotropin-Releasing Factor Receptor, type 2 (CRFR2) lacking the 8 to 10 N-terminal amino acids of native sauvagine. The present invention also relates to an antagonist of the ligand of the Corticotropin-Releasing Factor Receptor, type 2 (CRFR2) lacking the 11 N-terminal amino acids of native sauvagine, wherein the N-terminal amino acid of said antagonist is a charged amino acid. Furthermore, the present invention relates to a polynucleotide encoding the antagonist of the present invention, a vector comprising the polynucleotide of the present invention, and a host comprising the polynucleotide or the vector of the present invention. Also described are a method for producing the antagonist of the present invention, antibodies directed against the antagonist of the present invention, as well as anti-idiotypic antibodies directed against the antibody of the present invention. The present invention also relates to pharmaceutical and diagnostic compositions comprising the antagonist, the polynucleotide, the vector, the antibody, and/or the anti-idiotypic antibody of the present invention. Furthermore, the present invention relates to a kit comprising one or more of the above mentioned compounds of the present invention and to the use of one or more of these compounds for the preparation of a pharmaceutical composition for preventing and/or treating a Corticotropin-Releasing Factor Receptor, type 2 (CRFR2)-associated disease.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

# INTERNATIONAL SEARCH REPORT

national Application No

PCT/EP 99/05297

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K14/435 C07K16/18 A61K38/16 A61K39/395 C12N15/12  
C12N15/63 G01N33/53 G01N33/68 //C07K105:00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K C07K C12N G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GONZALEZ G C ET AL: "Presence of sauvagine-like epitopes in the interrenal gland of the bullfrog <i>Rana catesbeiana</i> ." CELL AND TISSUE RESEARCH, (1996 JAN) 283 (1) 117-23. , XP000881891 page 118, right-hand column	25-33
X	GAUDINO G ET AL: "Active peptides from amphibian skin are also amphibian neuropeptides." PEPTIDES, (1985) 6 SUPPL 3 209-13. , XP000881933 page 211, right-hand column -page 212, left-hand column	25-33
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

17 March 2000

Date of mailing of the international search report

12/04/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Mennessier, T



## INTERNATIONAL SEARCH REPORT

national Application No

PCT/EP 99/05297

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	LOVENBERG, TIMOTHY W. ET AL: "Corticotropin - releasing factor receptors: inhibitors, subtypes, pharmacology, localization, and their role in central nervous system function" CURR. PHARM. DES. (1995), VOLUME DATE 1995, 1(3), 305-16 , XP000882143 page 313, right-hand column -page 314, left-hand column	1-33
A	SPIESS, JOACHIM ET AL: "Molecular properties of the CRF receptor" TRENDS ENDOCRINOL. METAB. (MAY-JUNE 1998), 9(4), 140-145 , XP000881929 the whole document	1-33
A	BEHAN, DP ET AL: "Neurobiology of corticotropin releasing factor (CRF) receptors and CRF-binding protein: implications for the treatment of CNS disorders" MOL. PSYCHIATRY (1996), 1(4), 265-277 , XP000881969 page 265 -page 268, left-hand column page 272, right-hand column -page 273	1-33
A	US 4 474 765 A (PERSEO GIUSEPPE ET AL) 2 October 1984 (1984-10-02) the whole document	1-33
P,X	RUHMANN A ET AL: "Structural requirements for peptidic antagonists of the corticotropin - releasing factor receptor (CRFR): development of CRFR2beta-selective antisauvagine-30." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1998 DEC 22) 95 (26) 15264-9. , XP000882801 the whole document	1-33

# INTERNATIONAL SEARCH REPORT

Information on patent family members

national Application No

PCT/EP 99/05297

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4474765 A	02-10-1984	BE 896400 A	01-08-1983
		DE 3312399 A	13-10-1983
		FR 2524878 A	14-10-1983
		GB 2118190 A,B	26-10-1983
		JP 58183657 A	26-10-1983
		NL 8301281 A	01-11-1983

## INTERNATIONAL SEARCH REPORT

national Application No

PCT/EP 99/05297

<b>A. CLASSIFICATION OF SUBJECT MATTER</b>		
IPC 7	C07K14/435 C12N15/63	C07K16/18 G01N33/53
A61K38/16	A61K39/395	C12N15/12
G01N33/68	//C07K105:00	
According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b>		
Minimum documentation searched (classification system followed by classification symbols)		
IPC 7	A61K	C07K C12N G01N
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GONZALEZ G C ET AL: "Presence of sauvagine -like epitopes in the interrenal gland of the bullfrog <i>Rana catesbeiana</i> ." CELL AND TISSUE RESEARCH, (1996 JAN) 283 (1) 117-23. , XP000881891 page 118, right-hand column	25-33
X	GAUDINO G ET AL: "Active peptides from amphibian skin are also amphibian neuropeptides." PEPTIDES, (1985) 6 SUPPL 3 209-13. , XP000881933 page 211, right-hand column -page 212, left-hand column	25-33
	---	
	-/--	
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "Z" document member of the same patent family		
Date of the actual completion of the international search		Date of mailing of the international search report
17 March 2000		12/04/2000
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer  Mennessier, T

# INTERNATIONAL SEARCH REPORT

national Application No  
PCT/EP 99/05297

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>LOVENBERG, TIMOTHY W. ET AL: "Corticotropin - releasing factor receptors: inhibitors, subtypes, pharmacology, localization, and their role in central nervous system function" CURR. PHARM. DES. (1995), VOLUME DATE 1995, 1(3), 305-16 , XP000882143 page 313, right-hand column -page 314, left-hand column</p>	1-33
A	<p>SPIESS, JOACHIM ET AL: "Molecular properties of the CRF receptor" TRENDS ENDOCRINOL. METAB. (MAY-JUNE 1998), 9(4), 140-145 , XP000881929 the whole document</p>	1-33
A	<p>BEHAN, DP ET AL: "Neurobiology of corticotropin releasing factor (CRF) receptors and CRF-binding protein: implications for the treatment of CNS disorders" MOL. PSYCHIATRY (1996), 1(4), 265-277 , XP000881969 page 265 -page 268, left-hand column page 272, right-hand column -page 273</p>	1-33
A	<p>US 4 474 765 A (PERSEO GIUSEPPE ET AL) 2 October 1984 (1984-10-02) the whole document</p>	1-33
P,X	<p>RUHMANN A ET AL: "Structural requirements for peptidic antagonists of the corticotropin - releasing factor receptor (CRFR): development of CRFR2beta-selective antisaavagine-30." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1998 DEC 22) 95 (26) 15264-9. , XP000882801 the whole document</p>	1-33

# INTERNATIONAL SEARCH REPORT

Information on patent family members

national Application No



PCT/EP 99/05297

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4474765 A	02-10-1984	BE 896400 A	01-08-1983
		DE 3312399 A	13-10-1983
		FR 2524878 A	14-10-1983
		GB 2118190 A,B	26-10-1983
		JP 58183657 A	26-10-1983
		NL 8301281 A	01-11-1983

## PCT

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference C 2098 PCT		<b>FOR FURTHER ACTION</b> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/EP99/05297	International filing date (day/month/year) 23/07/1999	Priority date (day/month/year) 24/07/1998	
International Patent Classification (IPC) or national classification and IPC C07K14/435			
Applicant MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSC			
<p>1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of 8 sheets, including this cover sheet.</p> <p><input type="checkbox"/> This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of sheets.</p>			
<p>3. This report contains indications relating to the following items:</p> <ul style="list-style-type: none"><li>I <input checked="" type="checkbox"/> Basis of the report</li><li>II <input type="checkbox"/> Priority</li><li>III <input checked="" type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicability</li><li>IV <input type="checkbox"/> Lack of unity of invention</li><li>V <input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</li><li>VI <input type="checkbox"/> Certain documents cited</li><li>VII <input checked="" type="checkbox"/> Certain defects in the international application</li><li>VIII <input checked="" type="checkbox"/> Certain observations on the international application</li></ul>			
Date of submission of the demand  14/02/2000		Date of completion of this report  23.11.2000	
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465		Authorized officer  Mennessier, T  Telephone No. +49 89 2399 8687 	

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/EP99/05297

**I. Basis of the report**

1. This report has been drawn on the basis of *(substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments (Rules 70.16 and 70.17).):*

**Description, pages:**

1-31 as originally filed

**Claims, No.:**

1-33 as originally filed

**Drawings, sheets:**

1/4-4/4 as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/EP99/05297

☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

*(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)*

6. Additional observations, if necessary:

**III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability**

The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

☐ the entire international application.

☒ claims Nos. 25-33.

because:

☒ the said international application, or the said claims Nos. 30, 31 (partly), 32, 33 (each claim with respect to industrial applicability) relate to the following subject matter which does not require an international preliminary examination (*specify*):  
**see separate sheet**

☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):

☒ the claims, or said claims Nos. 25, 26, 27-33 (these latter claims partly) are so inadequately supported by the description that no meaningful opinion could be formed.

☐ no international search report has been established for the said claims Nos. .

2. A meaningful international preliminary examination report cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

☐ the written form has not been furnished or does not comply with the standard.

☐ the computer readable form has not been furnished or does not comply with the standard.

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

1. Statement



# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/EP99/05297

Novelty (N)	Yes:	Claims	1-24 and 27-33 (see point 3.a) of the suppl. sheet)
	No:	Claims	
Inventive step (IS)	Yes:	Claims	1-24 and 27-33 (see point 3.a) of the suppl. sheet)
	No:	Claims	
Industrial applicability (IA)	Yes:	Claims	1-24 and 31 (see point 3,c)i)) of the suppl. sheet)
	No:	Claims	

2. Citations and explanations  
**see separate sheet**

## VII. Certain defects in the international application

The following defects in the form or contents of the international application have been noted:  
**see separate sheet**

## VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:  
**see separate sheet**

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/EP99/05297

1. Documents cited in this report

Reference is made to the following documents which all cited in the international search report:

- # D1: *Cell and Tissue Research*, 283(1), 1996, 117-23
- # D2: *Peptides*, 6(suppl. 3), 1985, 209-13
- # D3: *Curr. Pharm. Des.*, 1(3), 1995, 305-16
- # D4: *Proceedings of the National Academy of Sciences of the United States of America*, 95(26), 1998 December 22), 15264-9

Document D4 to which the inventors contributed appears to be the non-patent literature counterpart of the present application under examination.

2. Comments with respect to item III

- a) Claims 30, 31 (insofar as it relates to "*the use of claim 30*"), 32 and 33 relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(i) PCT).
- b) Claims 25, 26 and 27-33, insofar as these latter claims relate to an antibody
  - (i) Antibodies to the antagonists as recited in claim 25 are only merely mentioned as being an aspect of the invention on page 9 of the description. No particular antibody is identified elsewhere in the description, which would recognize specifically an antagonist of the invention while being not or only poorly capable of binding to the native sauvagine from which the said antagonist is derived, and which would be distinguished from the prior art anti-sauvagine antibodies (see document D1, page 118, right-hand column; and document D2, pages 211 and 212).
  - (ii) Nor is any particular anti-idotypic antibody as recited in claim 26

described in the application. It has to be stressed that examples dealing with a particular antagonist are clearly inefficient at supporting claims directed to an anti-idotypic antibody directed against an antibody which is itself directed against the said antagonist. As no such anti-idotypic antibody is described, it would be simply impossible to assess whether claims relating thereto involve an inventive step.

- (iii) Therefore, the subject-matter of claims 25-26 is so inadequately supported by the description that no meaningful opinion could be formed, this conclusion extending de facto to the subject-matter of claims 27-33, insofar as it is defined with reference to any of the said antibodies.

3. Comments with respect to item V

a) Preliminary remarks

The following comments with respect to novelty, inventive step and industrial applicability are made only with regard to claim 1-24 (as a whole) and claims 27-33 (only partly, i.e., only with respect to their subject-matter which does not relate to any antibody).

b) Novelty and inventive step (Article 33(2) and 33(3) PCT)

The various aspects of the invention as defined in the afore-mentioned claims relies on the design, synthesis and characterisation by the inventors of a high-affinity mCRFR2 $\beta$ -specific peptide antagonist. The said antagonist has its amino acid sequence based on native sauvagine. It is a truncated analog thereof lacking the 10 N-terminal amino acids. Such an analog or related truncated analogs appear not to be disclosed in the state of the art.

The technical problem solved by the invention may be regarded as the development of CRFR-2 specific antagonists to (i) permit discrimination between receptor type-specific functions, (ii) serve as a useful tool to detect CRFR2 and elucidate its functional role in the brain and peripheral organs,

and (iii) be efficient at treating a CRFR2-associated disease.

Focusing on the development of non-peptide antagonists (see D3, page 313, right-hand column) the state of the art would lead the person skilled in the art away from the solution proposed by the invention.

Therefore, it may be acknowledged that the various aspects of the invention as defined in the afore-mentioned claims are new and involve an inventive step.

c) Industrial applicability (Article 33(4) PCT)

- (i) The subject-matter of claims 1-24 and that of claim 31, insofar as it relates to "*The antagonist of any one of claims 1 to 18, or 24*", is considered to be susceptible of industrial applicability.
- (ii) For the assessment of the present claims 30, 31 (insofar as it relates to "*the use of claim 30*"), 32 and 33 on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

d) P-document

Should the various aspects of the claimed invention appear not to be entitled to the claimed priority date, document D4 which is cited in the international search report as a P-document should be taken into consideration when examining whether the invention is new and involves an inventive step.

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/EP99/05297

4. Comments with respect to item VII

The Applicants are advised that some national/regional patent offices such as the EPO would object to a claim which as present claim 31 is directed to more than one object, the claimed objects being of different categories.

5. Comments with respect to item VIII

- a) As it has not been explicitly specified in claim 1 that the amino acid sequence of the antagonist is based on sauvagine the claimed subject-matter is considered not to be unambiguously defined. Claim 1 is therefore objected to under Article 6 PCT.
- b) In view of the comments made at point 3 above, claims 25 to 33 are objected to under Article 6 PCT.

VOSSIUS & PARTNER  
PATENTANWÄLTE  
SIEBERTSTR. 4  
81675 MÜNCHEN

New PCT Patent Application  
Max-Planck-Gesellschaft zur  
Förderung der Wissenschaften e.V.  
Our Ref: C 2098 PCT

23. Juli 1999

**Antagonists specific for the corticotropin-releasing factor receptor  
type 2 (CRFR2)**

The present invention relates to an antagonist of the ligand of the Corticotropin-Releasing Factor Receptor, type 2 (CRFR2) lacking the 8 to 10 N-terminal amino acids of native sauvagine. The present invention also relates to an antagonist of the ligand of the Corticotropin-Releasing Factor Receptor, type 2 (CRFR2) lacking the 11 N-terminal amino acids of native sauvagine, wherein the N-terminal amino acid of said antagonist is a charged amino acid. Furthermore, the present invention relates to a polynucleotide encoding the antagonist of the present invention, a vector comprising the polynucleotide of the present invention, and a host comprising the polynucleotide or vector of the present invention. Also described are a method for producing the antagonist of the present invention, antibodies directed against the antagonist of the present invention, as well as anti-idiotypic antibodies directed against the antibody of the present invention. The present invention also relates to pharmaceutical and diagnostic compositions comprising the antagonist, the polynucleotide, the vector, the antibody, and/or the anti-idiotypic antibody of the present invention. Furthermore, the present invention relates to a kit comprising one or more of the above mentioned compounds of the present invention and to the use of one or more of these compounds for the preparation of a pharmaceutical composition for preventing and/or treating a Corticotropin-Releasing Factor Receptor, type 2 (CRFR2)-associated disease.

Corticotropin-releasing factor (CRF), believed to synchronize the endocrine, autonomic, immunologic and behavioral responses to stress, was characterized as a 41-residue polypeptide (Spiess, J., J. Rivier, C. Rivier, and W. Vale, *Proc. Natl. Acad. Sci. USA* **78**:6517-6521, 1981) on the basis of its ability to stimulate the secretion of adrenocorticotrophic hormone (ACTH) from the anterior pituitary (Vale, W., J. Spiess, C. Rivier, and J. Rivier, *Science* **213**:1394-1397, 1981).

CRF exhibits its activity through G protein-coupled receptors. CRF receptor, type 1 (CRFR1), mainly found in pituitary and brain was cloned from human, mouse, rat, chicken, and frog (Vita, N., P. Laurent, S. Lefort, P. Chalon, J.-M. Lelias, M. Kaghad, G. Le Fur, D. Caput, and P. Ferrara, *FEBS Lett.* **335**:1-5, 1993; Chen, R., K. A. Lewis, M. H. Perrin, and W. Vale, *Proc. Natl. Acad. Sci. USA* **90**:8967-8971, 1993; Perrin, M. H., C. J. Donaldson, R. Chen, K. A. Lewis, and W. Vale, *Endocrinology* **133**:3058-3061, 1993; Chang, C.-P., R. V. Pearce II, S. O'Connell, and M. G. Rosenfeld, *Neuron* **11**:1187-1195, 1993; Yu, J., L. Y. Xie, and A. B. Abou-Samra, *Endocrinology* **137**:192-197, 1996; Dautzenberg, F. M., K. Dietrich, M. R. Palchaudhuri, and J. Spiess, *J. Neurochem.* **69**:1640-1649, 1997). cDNAs coding for two splice variants of CRF receptor, type 2, CRFR2 $\alpha$  and CRFR2 $\beta$ , were cloned from brain, heart, and skeletal muscle (Lovenberg, T. W., C. W. Liaw, D. E. Grigoriadis, W. Clevenger, D. T. Chalmers, E. B. De Souza, and T. Oltersdorf, *Proc. Natl. Acad. Sci. USA* **92**:836-840, 1995; Perrin, M., C. Donaldson, R. Chen, A. Blount, T. Berggren, L. Bilezikjian, P. Sawchenko, and W. Vale, *Proc. Natl. Acad. Sci. USA* **92**:2969-2973, 1995; Kishimoto, T., R. V. Pearce II, C. R. Lin, and M. G. Rosenfeld, *Proc. Natl. Acad. Sci. USA* **92**:1108-1112, 1995; Stenzel, P., R. Kesterson, W. Yeung, R. D. Cone, M. B. Rittenberg, and M. P. Stenzel-Poore, *Mol. Endocrinol.* **9**:637-645, 1995). In rodents, CRFR2 $\alpha$  has been exclusively found in the central nervous system (CNS), whereas CRFR2 $\beta$  is predominantly distributed in the periphery. In humans, both receptor subtypes have been found in the CNS (Valdeaire, O., T. Giller, V. Breu, J. Gottowik, and G. Kilpatrick, *Biochim. Biophys. Acta* **1352**: 129-132, 1997). Recently, it has been proposed that urocortin (Ucn), a natural CRF analog, is the endogenous ligand to CRFR2 (Vaughan, J., C. Donaldson, J. Bittencourt, M. H. Perrin, K. Lewis, S. Sutton, R. Chan, A. V. Turnbull, D. Lovejoy, C. Rivier, J. Rivier, P. E. Sawchenko, and W. Vale, *Nature (London)* **378**:237-292, 1995).

CRF is assumed to play a major role in a number of neuropsychiatric diseases including affective disorders, anxiety disorders, anorexia nervosa and Alzheimer's disease (Behan, D. P., S. C. Heinrichs, J. C. Trancoso, X. J. Liu, C. H. Kavas, N. Ling, and E. B. De Souza, *Nature (London)* **378**:284-287, 1995). There is substantial interest in the design and synthesis of CRF antagonists acting selectively at one of the different CRF forms. After the discovery of potent peptide antagonists based on the N-terminally truncated amino acid sequence of human/rat CRF (h/rCRF) (Rivier, J., C.

Rivier, R. Galyean, A. Miranda, C. Miller, A. G. Craig, G. Yamamoto, M. Brown, and W. Vale, *J. Med. Chem.* **36**:2851-2859, 1993; Hernandez, J. F., W. Kornreich, C. Rivier, A. Miranda, G. Yamamoto, J. Andrews, Y. Tache, W. Vale, and J. Rivier, *J. Med. Chem.* **36**:2860-2867, 1993; Miranda, A., S. C. Koerber, J. Gulyas, S. L. Lahrchi, A. G. Craig, A. Corrigan, A. Hagler, C. Rivier, and J. Rivier, *J. Med. Chem.* **37**:1450-1459, 1994; Gulyas, J., C. Rivier, M. Perrin, S. C. Koerber, S. Sutton, A. Corrigan, S. L. Lahrchi, A. G. Craig, W. Vale, and J. Rivier, *Proc. Natl. Acad. Sci. USA* **92**:10575-10579, 1995; Miranda, A., S. L. Lahrchi, J. Gulyas, S. C. Koerber, A. G. Craig, A. Corrigan, C. Rivier, W. Vale, and J. Rivier, *J. Med. Chem.* **40**:3651-3658, 1997), several CRFR1-selective nonpeptidic antagonists have been developed (Chen, C., R. Dagnino, Jr., E. B. De Souza, D. E. Grigoriadis, C. Q. Huang, Kjung-II Kim, Z. Liu, T. Moran, T. R. Webb, J. P. Whitten, Y. F. Xie, and J. R. McCarthy, *J. Med. Chem.* **39**:4358-4360, 1996; Schulz, D. W., R. S. Mansbach, J. Sprouse, J. P. Braselton, J. Collins, M. Corman, A. Dunaiskis, S. Faraci, A. W. Schmidt, T. Seeger, P. Seymour, F. D. Tingley III, E. N. Winston, Y. L. Chen, and J. Heym, *Proc. Natl. Acad. Sci. USA* **93**:10477-10482, 1996; Christos, T. E., and A. Arvanitis, *Expert Opinion On Therapeutic Patents* **8**: 143-152, 1998) which attenuate CRF-mediated seizure (Baram, T. Z., D. T. Chalmers, C. Chen, Y. Koutsoukos, and E. B. De Souza, *Brain Research* **770**: 89-95, 1997) or interleukin-1 $\beta$ -induced fever or exhibit anxiolytic activity *in vivo* (Lundkvist, J., Z. Chai, R. Teheranian, H. Hasanvan, T. Bartfai, F. Jenck, U. Widmer, and J.-L. Moreau, *Eur. J. Pharmacol.* **309**: 195-200, 1996). However, the fact that CRF antagonist  $\alpha$ -helical CRF<sub>(9-41)</sub> exhibits different inhibitory potencies in three different *in vivo* bioassay systems (Fisher, L., C. Rivier, J. Rivier, and M. Brown, *Endocrinology* **129**:1312-1316, 1991) suggests that distinct physiological functions of endogenous CRF or Ucn are mediated via CRFR1, CRFR2 or both receptor types.

Thus, the technical problem underlying the present invention was to develop CRFR2-specific antagonists to permit discrimination between receptor type-specific functions, e.g., in the brain and peripheral organs.

The solution to said technical problem is provided by the embodiments characterized in the claims.



Accordingly, the present invention relates to an antagonist of the ligand of the Corticotropin-Releasing Factor Receptor, type 2 (CRFR2) lacking the 8 to 10 N-terminal amino acids of native sauvagine.

In accordance with the present invention the term "ligand" encompasses any molecule capable of specifically binding to the Corticotropin-Releasing Factor Receptor, type 2 (CRFR2), including, e.g., (the) naturally occurring, endogenous ligand(s) of CRFR2, or any compound(s) recombinantly or chemically synthesized or biochemically modified and capable of binding and activating CRFR2.

The term "CRFR2-specific", "CRFR2-selective", "CRFR2-specificity" or "CRFR2-selectivity" as used in accordance with the present invention denotes a value which is higher than 30, preferably higher than 45, and more preferred higher than 70, and calculated according to the equation mentioned in the legend to table 1. Thus, as used in accordance with the present invention, e.g., a "CRFR2-specific" antagonist is not meant to exclusively bind to CRFR2, but to bind to CRFR2 with an at least 30-fold, preferably 45-fold, and more preferred 70-fold higher selectivity than astressin, which exhibits a similar affinity for CRFR1 and CRFR2, in particular CRFR2 $\beta$ .

Studies which have been carried out in accordance with the present invention surprisingly revealed that deletion of the 8 to 10 N-terminal amino acids of native sauvagine, which is a potent non-selective activator of CRFR, renders this compound a highly specific antagonist for CRFR2.

In a preferred embodiment the antagonist of the present invention lacks the 10 N-terminal amino acids of native sauvagine.

In a more preferred embodiment the antagonist of the present invention comprises the amino acid sequence Xaa<sub>1</sub>-Xaa<sub>2</sub>-Leu-Leu-Arg-Lys-Met-Ile-Glu-Ile-Glu-Lys-Gln-Glu-Lys-Glu-Lys-Gln-Gln-Ala-Ala-Asn-Asn-Arg-Leu-Leu-Leu-Asp-Thr-Ile-NH<sub>2</sub>, wherein Xaa<sub>1</sub> is a neutral amino acid, and Xaa<sub>2</sub> is a charged amino acid.

In another more preferred embodiment of the antagonist of the present invention, Xaa<sub>1</sub> is a hydrophobic amino acid, and Xaa<sub>2</sub> is Glu or His.

In an even more preferred embodiment of the antagonist of the present invention Xaa<sub>1</sub> is Leu.

In a further more preferred embodiment, Xaa<sub>1</sub> is a polar amino acid and Xaa<sub>2</sub> is Glu or His.

In a still more preferred embodiment of the antagonist of the present invention Xaa<sub>1</sub> is Tyr.

It is envisaged that antagonists of the present invention comprising Tyr as the N-terminal amino acid can be advantageously used to be radioactively labelled with, e.g., <sup>125</sup>I. Such compounds may then be employed in in vivo or in vitro experiments for the detection of CRFR2 binding sites. Although antagonists <sup>125</sup>I-labelled via His are also encompassed by the present invention, antagonists labelled via Tyr are preferred because the labelling reaction is easier to perform from the technical point of view, and the labelled compound is more stable and, therefore, easier to handle.

In a further even more preferred embodiment of the antagonist of the present invention Xaa<sub>1</sub> is in the D-configuration.

In a further still more preferred embodiment of the antagonist of the present invention Xaa<sub>1</sub> is D-Leu or D-Tyr.

In a most preferred embodiment of the antagonist of the present invention Xaa<sub>2</sub> is Glu.

In another still more preferred embodiment of the antagonist of the present invention Xaa<sub>1</sub> is D-Phe.

In another most preferred embodiment of the antagonist of the present invention Xaa<sub>2</sub> is His.

In another embodiment, the present invention relates to an antagonist of the ligand of

the Corticotropin-Releasing Factor Receptor, type 2 (CRFR2) lacking the 11 N-terminal amino acids of native sauvagine, wherein the N-terminal amino acid of said antagonist is a charged amino acid.

In a preferred embodiment, said charged amino acid is positively charged.

In a more preferred embodiment, said charged amino acid is His.

In another preferred embodiment, the antagonist of the present invention comprises a phenyldiazirine group coupled to the N-terminal amino acid of said antagonist.

Antagonists of the present invention comprising a phenyldiazirine group are envisaged to be used, e.g., in photoaffinity labelling experiments. Accordingly, these compounds can be advantageously used to characterize antagonistic binding sites of CRFR2 $\beta$  receptor systems.

In a more preferred embodiment, said phenyldiazirine group is a 4-(1-azi-2,2,2-trifluoroethyl)benzoyl (ATB)-group.

In a further embodiment the present invention relates to a polynucleotide encoding the antagonist of the present invention.

The polynucleotide of the present invention may be, e.g., DNA, cDNA, RNA or synthetically produced DNA or RNA or a recombinantly produced chimeric nucleic acid molecule comprising any of those polynucleotides either alone or in combination.

In another embodiment the present invention relates to a vector comprising the polynucleotide of the present invention.

The vector of the present invention may be, e.g., a plasmid, cosmid, virus, bacteriophage or another vector used conventionally in genetic engineering, and may comprise further genes such as marker genes which allow for the selection of said

vector in a suitable host cell and under suitable conditions.

In a preferred embodiment of the vector of the present invention the polynucleotide is operatively linked to an expression control sequence.

Said expression control sequence allows expression in prokaryotic or eukaryotic cells. Expression of said polynucleotide comprises transcription of the polynucleotide into a translatable mRNA. Regulatory elements ensuring expression in eukaryotic cells, preferably mammalian cells, are well known to those skilled in the art. They usually comprise regulatory sequences ensuring initiation of transcription and optionally poly-A signals ensuring termination of transcription and stabilization of the transcript. Additional regulatory elements may include transcriptional as well as translational enhancers, and/or naturally-associated or heterologous promoter regions.

Possible regulatory elements permitting expression in prokaryotic host cells comprise, e.g., the  $P_L$ , lac, trp or tac promoter in *E. coli*, and examples for regulatory elements permitting expression in eukaryotic host cells are the AOX1 or GAL1 promoter in yeast or the CMV-, SV40-, RSV-promoter (Rous sarcoma virus), CMV-enhancer, SV40-enhancer or a globin intron in mammalian and other animal cells. Beside elements which are responsible for the initiation of transcription such regulatory elements may also comprise transcription termination signals, such as the SV40-poly-A site or the tk-poly-A site, downstream of the polynucleotide. Furthermore, depending on the expression system used leader sequences capable of directing the polypeptide to a cellular compartment or secreting it into the medium may be added to the coding sequence of the polynucleotide of the invention and are well known in the art. The leader sequence(s) is (are) assembled in appropriate phase with translation, initiation and termination sequences, and preferably, a leader sequence capable of directing secretion of translated protein, or a portion thereof, into the periplasmic space or extracellular medium. Optionally, the heterologous sequence can encode a fusion protein including an C- or N-terminal identification peptide imparting desired characteristics, e.g., stabilization or simplified purification of expressed recombinant product. In this context, suitable expression vectors are known in the art such as Okayama-Berg cDNA expression vector pcDV1 (Pharmacia), pCDM8, pRc/CMV, pcDNA1, pcDNA3 (In-vitrogene), or pSPORT1

(GIBCO BRL).

Preferably, the expression control sequences will be eukaryotic promoter systems in vectors capable of transforming or transfecting eukaryotic host cells, but control sequences for prokaryotic hosts may also be used. Once the vector has been incorporated into the appropriate host, the host is maintained under conditions suitable for high level expression of the nucleotide sequences.

Furthermore, the present invention relates to a host comprising the polynucleotide or vector of the present invention.

Said host may be a prokaryotic or eukaryotic cell. The polynucleotide or vector of the invention which is present in the host cell may either be integrated into the genome of the host cell or it may be maintained extrachromosomally.

The host cell can be any prokaryotic or eukaryotic cell, such as a bacterial, insect, fungal, plant, animal or human cell. Preferred fungal cells are, for example, those of the genus *Saccharomyces*, in particular those of the species *S. cerevisiae*. The term "prokaryotic" is meant to include all bacteria which can be transformed or transfected with a polynucleotide or vector of the present invention for the expression of the antagonist of the present invention. Prokaryotic hosts may include gram negative as well as gram positive bacteria such as, for example, *E. coli*, *S. typhimurium*, *Serratia marcescens* and *Bacillus subtilis*. The term "eukaryotic" is meant to include yeast, higher plant, insect and preferably mammalian cells. Depending upon the host employed in a recombinant production procedure, the antagonist encoded by the polynucleotide of the present invention may or may not be post-translationally modified. A polynucleotide of the invention can be used to transform or transfect the host using any of the techniques commonly known to those of ordinary skill in the art. Furthermore, methods for preparing fused, operably linked genes and expressing them in, e.g., mammalian cells and bacteria are well-known in the art (e.g. Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1989). The genetic constructs and methods described therein can be utilized for expression of the antagonist of the present invention in eukaryotic or prokaryotic hosts. In general, expression vectors containing promoter sequences which facilitate the efficient transcription of the inserted polynucleotide are used in connection with the host. The expression vector typically contains an origin of

replication, a promoter, and a terminator, as well as specific genes which are capable of providing phenotypic selection of the transformed cells. Furthermore, transgenic animals, preferably mammals, comprising host cells of the invention may be used for the large scale production of the antagonist of the present invention.

The present invention also relates to a method for producing the antagonist of the present invention, said method comprising culturing the host of the present invention under conditions that cause the synthesis of said antagonist, and recovering said antagonist from the culture.

Depending on the specific construct and condition used, the antagonist may be recovered from the host cells, from the culture medium or from both.

The present invention further relates to an antagonist obtainable by the method of the present invention.

Alternatively, the antagonist of the present invention can be chemically synthesized according to methods well known in the art, e.g., solid phase synthesis with Fmoc or t-boc chemistry (see also, e.g., Rühmann, A., A. K. E. Köpke, F. M. Dautzenberg, and J. Spiess, *Proc. Natl. Acad. Sci. USA* **93**:10609-10613, 1996).

In another embodiment the present invention relates to an antibody directed against the antagonist of the present invention.

In a further embodiment the present invention relates to an anti-idiotypic antibody directed against the antibody of the present invention.

The antibodies of the present invention may be monoclonal antibodies, polyclonal antibodies, single chain antibodies, humanized antibodies, or fragments thereof that specifically bind the antagonist of the present invention or the antibody directed against the antagonist of the present invention. Bispecific antibodies, synthetic antibodies, antibody fragments, such as Fab, Fv or scFv fragments etc., or chemically modified derivatives of any of these are also encompassed by the present invention. Monoclonal antibodies can be prepared, for example, by the techniques as originally described in Köhler and Milstein, *Nature* **256** (1975), 495, and Galfré, *Meth. Enzymol.*

73 (1931), 3, which comprise the fusion of mouse myeloma cells to spleen cells derived from immunized mammals with modifications developed by the art. Furthermore, antibodies or fragments thereof can be obtained by using methods which are described, e.g., in Harlow and Lane "Antibodies, A Laboratory Manual", CSH Press, Cold Spring Harbor, 1988. The production of chimeric antibodies is described, for example, in WC89/09622. Methods for the production of humanized antibodies are described in, e.g., EP-A1 0 239 400 and WO90/07861. A further source of antibodies to be utilized in accordance with the present invention are so-called xenogenic antibodies. The general principle for the production of xenogenic antibodies such as human antibodies in mice is described in, e.g., WO 91/10741, WO 94/02602, WO 96/34096 and WO 96/33735. As discussed above, the antibodies of the invention may exist in a variety of forms besides complete antibodies; including, for example, Fv, Fab and F(ab)2, as well as in single chains; see e.g. WO88/09344.

The present invention also relates to a pharmaceutical composition comprising the antagonist, the polynucleotide, the vector, the antibody and/or the anti-idiotypic antibody of the present invention and optionally a pharmaceutically acceptable carrier and/or diluent.

Examples of suitable pharmaceutical carriers are well known in the art and include phosphate buffered saline solutions, water, emulsions, such as oil/water emulsions, various types of wetting agents, sterile solutions etc. Compositions comprising such carriers can be formulated by well known conventional methods. These pharmaceutical compositions can be administered to the subject at a suitable dose. Administration of the suitable compositions may be effected by different ways, e.g., by intravenous, intraperitoneal, subcutaneous, intramuscular, topical or intradermal administration. The dosage regimen will be determined by the attending physician and clinical factors. As is well known in the medical arts, dosages for any one patient depends upon many factors, including the patient's size, body surface area, age, the particular compound to be administered, sex, time and route of administration, general health, and other drugs being administered concurrently. The compositions of the invention may be administered locally or systemically. Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene

glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other additives may also be present such as, for example, antimicrobials, anti-oxidants, chelating agents, and inert gases and the like. Furthermore, the pharmaceutical composition of the invention may comprise further agents depending on the intended use of the pharmaceutical composition.

Furthermore, the present invention relates to a diagnostic composition comprising the antagonist, the polynucleotide, the vector, the antibody and/or the anti-idiotypic antibody of the present invention.

The present invention further relates to a kit comprising the antagonist, the polynucleotide, the vector, the antibody and/or the anti-idiotypic antibody of the present invention.

The components of the diagnostic composition and/or the kit of the invention may be packaged in containers such as vials, optionally in buffers and/or solutions. If appropriate, one or more of said components may be packaged in one and the same container. Additionally or alternatively, one or more of said components may be adsorbed to solid support such as, e.g., a nitrocellulose filter or nylon membrane, or to the well of a microtiter plate.

In another embodiment the present invention relates to the use of the antagonist, the polynucleotide, the vector, the antibody and/or the anti-idiotypic antibody of the present invention for the preparation of a pharmaceutical composition for preventing and/or treating a Corticotropin-Releasing Factor Receptor, type 2 (CRFR2)-associated disease.

In a preferred embodiment of the antagonist or the use of the present invention said CRFR2 is CRFR2 $\alpha$  or CRFR2 $\beta$ .



In another preferred embodiment the use of the present invention is for preventing and/or treating affective disorders, gastric intestinal diseases, cardiopathic diseases, psychiatric diseases, preferably eating disorders, anxiety disorders or anorexia nervosa, and/or Alzheimer's disease.

The present invention also relates to the use of the antagonist, the polynucleotide, the vector, the antibody and/or the anti-idiotypic antibody of the present invention for the investigation of CRF receptor type-specific functions.

The documents cited herein are herewith incorporated by reference.

Abbreviations used throughout the description, the figure legends, and the examples are as follows: IUPAC rules are used for the nomenclature of peptides including one letter codes for amino acids; AAA: amino acid analysis; ACTH: adrenocorticotrophic hormone; ANOVA: one-way analysis of variance; astressin: {cyclo(30-33)[DPhe<sup>12</sup>, Nle<sup>21,38</sup>, Glu<sup>30</sup>, Lys<sup>33</sup>]h/rCRF<sub>(12-41)}</sub>; BSA: bovine serum albumin; cAMP: adenosine 3', 5'-cyclic monophosphate; CRF: corticotropin-releasing factor (h = human, o = ovine, r = rat); CRFR: CRF receptor; DIEA: *N,N*-diisopropylethylamine; DMF: dimethylformamide; Fmoc: 9-fluorenylmethoxycarbonyl; HBTU: O-(benzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium hexafluorophosphate; HEK: human embryonic kidney; HOAc: acetic acid; HOBt: 1-hydroxybenzotriazole; <sup>125</sup>I: <sup>125</sup>I-iodinated; MeCN: acetonitrile; MS: mass spectrometry; NMP: *N*-methylpyrrolidone-2; OAl: O-allyl; OAlloc: O-allyloxycarbonyl; Pd<sup>0</sup>[PPh<sub>3</sub>]<sub>4</sub>: tetrakis-(triphenylphosphine)-palladium; RP-HPLC: reverse phase high-performance liquid chromatography; SAR: structure-activity relationship; Svg: sauvagine; TFA: trifluoroacetic acid; Ucn: urocortin.

The figures show:

#### Figure 1:

Comparison of the amino acid sequence of human/rat corticotropin-releasing factor (h/rCRF) with ovine corticotropin-releasing factor (oCRF), rat urocortin (rUcn), sauvagine (Svg), and astressin. Identical amino acids are shaded.

Figure 2:

Chemical cross-linking of [ $^{125}$ I-Tyr $^0$ ]oCRF or [ $^{125}$ I-Tyr $^0$ ]Svg to membrane homogenates of human embryonic kidney (HEK) 293 cells stably transfected with cDNA coding for rat CRF receptor, type 1 (rCRFR1) (lanes 1 and 2) or mouse CRF receptor, type 2 $\beta$  (mCRFR2 $\beta$ ) (lanes 3 and 4), respectively. Fifty  $\mu$ g of total membrane protein was labeled with approximately 100,000 cpm of [ $^{125}$ I-Tyr $^0$ ]oCRF (lanes 1 and 2) and [ $^{125}$ I-Tyr $^0$ ]Svg (lanes 3 and 4), and incubated (37°C, 30 min) in the presence (lane 2 and 4) or absence (lane 1 and 3) of 2000 units PNGase.

Figure 3:

Displacement of [ $^{125}$ I-Tyr $^0$ ]oCRF (A) or [ $^{125}$ I-Tyr $^0$ ]Svg (B) bound to membrane homogenates of HEK 293 cells stably transfected with cDNA coding for rat CRF receptor, type 1 (rCRFR1) (A), or mouse CRF receptor, type 2 $\beta$  (mCRFR2 $\beta$ ) (B), by oCRF (compound 1,  $\circ$ ), Svg (compound 2,  $\square$ ), astressin (compound 3,  $\Delta$ ), [DPhe $^{12}$ , Nle $^{21,38}$ ]h/rCRF $_{(12-41)}$  (compound 5,  $\blacktriangle$ ), [DPhe $^{12}$ ]oCRF $_{(12-41)}$  (compound 6,  $\bullet$ ), [DPhe $^{11}$ ]rUcn $_{(11-40)}$  (compound 7,  $\blacklozenge$ ), and [DPhe $^{11}$ , His $^{12}$ ]Svg $_{(11-40)}$  (compound 11,  $\blacksquare$ ). The error bars represent the SEM and are not shown when smaller than the symbol size.

Figure 4:

Potency of 1 $\mu$ M CRF antagonist (compounds 3-14) to stimulate cAMP production in transfected HEK 293 cells (%IA, intrinsic activity) (A, B). Efficacy of CRF antagonists (c = 1 $\mu$ M for rCRFR1 and c = 10nM for mCRFR2 $\beta$ ) to inhibit cAMP production in transfected HEK 293 cells stimulated by 1nM oCRF (compound 1 for rCRFR1) and 1nM Svg (compound 2 for mCRFR2 $\beta$ ) (relative *in vitro* potency) (C, D). Data is the mean from 3-11 experiments. The error bars represent the SEM.

The examples illustrate the invention.

Example 1: Synthesis and analysis of peptides

Different truncated and conformationally constrained analogs of corticotropin-releasing factor (CRF) were synthesized on the basis of the amino acid sequences of human/rat CRF (h/rCRF), ovine CRF (oCRF), rat urocortin (rUcn), or sauvagine (Svg) (0.1 mmol scale) with Fmoc chemistry on TentaGel S RAM resin (Rapp, Tübingen, F.R.G.) with a model ABI 433A peptide synthesizer (Applied Biosystems). Comparison of the amino acid sequences of oCRF, rUcn and Svg with the sequence of h/rCRF reveals 45-83% amino acid identity. The CRF ligands mentioned share high amino acid identity at the N-terminus (47%) stretching from amino acid 2-20 (h/rCRF and oCRF) and 1-19 (rUcn and Svg), but little at the C-terminus (14%) of the peptides stretching from amino acid 21-41 and 20-40, respectively (Fig. 1). It was assumed that the ligand receptor interactions of the truncated forms of the CRF peptides ranging from amino acid 11-40 (rUcn and Svg) or 2-41 (h/rCRF and oCRF) acted differently than the full-length CRF peptides on CRFR1 or CRFR2 (Dautzenberg, F. M., K. Dietrich, M. R. Palchaudhuri, and J. Spiess, *J. Neurochem.* **69**:1640-1649, 1997; Vaughan, J., C. Donaldson, J. Bittencourt, M. H. Perrin, K. Lewis, S. Sutton, R. Chan, A. V. Turnbull, D. Lovejoy, C. Rivier, J. Rivier, P. E. Sawchenko, and W. Vale, *Nature (London)* **378**:287-292, 1995; Donaldson, C. J., S. W. Sutton, M. H. Perrin, A. Z. Corrigan, K. A. Lewis, J. E. Rivier, J. M. Vaughan, and W. W. Vale, *Endocrinology* **137**:2167-2170, 1996; Gottowik, J., V. Goetschy, S. Henriot, E. Kitas, B. Fluhman, R. G. Clero, J. L. Moreau, F. J. Monsma, and G. J. Kilpatrick, *Neuropharmacol.* **36**:1439-1446, 1997).

For the synthesis of the cyclized CRF analogs, astressin and cyclo(29-32)[DPhe<sup>11</sup>, Glu<sup>29</sup>, Lys<sup>32</sup>]rUcn<sub>(11-40)</sub>, the amino acid derivatives Fmoc-L-Glu(OAll)-OH and Fmoc-L-Lys(Alloc)-OH (PerSeptive Biosystems GmbH, Hamburg, F.R.G.) were used. The side-chain-protected peptides were reacted with Pd<sup>0</sup>[PPh<sub>3</sub>]<sub>4</sub> in HOAc/N-methylaniline/dichloromethane (v/v; 2:1:40) for three hours and then cyclized with HOBt/HBTU in DMF and DIEA in NMP for eight hours. After removal of the N-terminal Fmoc group with piperidine in NMP, the peptides were cleaved from the resin under standard conditions. The crude peptides were purified by preparative reverse phase high-performance liquid chromatography (RP-HPLC) performed on a Waters Prep Nova-Pak HR C<sub>18</sub> silica gel column (5 x 30 cm, 5-µm particle size, 6-nm pore size) with a mixture of aqueous 0.1% trifluoroacetic acid and MeCN (see Table 5). The mass spectra of the purified peptides were measured with a plasma desorption mass

spectrometer (Biolon 20, Uppsala). Amino acid analysis (AAA) was performed after hydrolysis of peptides (6 N HCl, 3 hr, 150°C) with a Beckman High Performance Analyzer System 6300 (Beckman, San Remo).

#### Example 2: Binding of CRF agonists and antagonists to rCRFR1

CRF agonists and antagonists were tested in an *in vitro* assay for their ability to displace [ $^{125}$ I-Tyr $^0$ ]oCRF or [ $^{125}$ I-Tyr $^0$ ]Svg from membranes of HEK-rCRFR1 cells (Rühmann, A., A. K. E. Köpke, F. M. Dautzenberg, and J. Spiess, *Proc. Natl. Acad. Sci. USA* **93**:10609-10613, 1996) or HEK-mCRFR2 $\beta$  cells (Kishimoto, T., R. V. Pearce II, C. R. Lin, and M. G. Rosenfeld, *Proc. Natl. Acad. Sci. USA* **92**:1108-1112, 1995). Binding assays were performed in 96-well MultiScreen plates (Millipore, Eschborn, Germany) with G $\frac{1}{2}$ /B filters (pore size 1.0  $\mu$ m). Fifty-microliters of membrane suspension (25  $\mu$ g of protein from HEK-rCRFR1 cells; 50  $\mu$ g of protein from HEK-mCRFR2 $\beta$  cells) was added to a plate containing CRF peptides (c = 0-1  $\mu$ M) and 50,000 cpm of either [ $^{125}$ I-Tyr $^0$ ]oCRF (specific activity 81.4 TBq/mmol, 68.25 pM, DuPont NEN, Boston) for the analysis of rCRFR1 or [ $^{125}$ I-Tyr $^0$ ]Svg (specific activity 81.4 TBq/mmol, 68.25 pM, DuPont NEN, Boston) for the analysis of mCRFR2 $\beta$  in 100  $\mu$ l incubation buffer (50 mM Tris/Cl, 5 mM MgCl $_2$ , 2 mM EGTA, 100,000 kallikrein inhibitor units per liter of Trasylol (Bayer, Leverkusen), 1 mM dithiothreitol, 1 mg/ml BSA, pH 7.4). After incubation (60 min, 23°C), membrane suspension was aspirated through the plate, followed by two washes with assay buffer (0.2 ml, 23°). Radioactivity of the punched filters was measured with a 1470 WIZARD automatic gamma counter (Berthold, Hannover). Specific binding of [ $^{125}$ I-Tyr $^0$ ]oCRF or [ $^{125}$ I-Tyr $^0$ ]Svg to membranes of transfected cells was calculated by subtraction of unspecific binding found in the presence of 1  $\mu$ M of nonlabeled ligand from total binding. Data analysis was achieved with the nonlinear curve fitting program LIGAND. Statistical analysis was performed with ANCOVA, and significant differences between groups were determined by post hoc comparison using the Dunn test.

#### Example 3: Chemical cross-linking with [ $^{125}$ I-Tyr $^0$ ]oCRF or [ $^{125}$ I-Tyr $^0$ ]Svg

Chemical cross-linking was carried out in 1.5 ml polypropylene tubes (Sigma, Deisenhofen, Germany) as for the binding assay except that no BSA was used.

Samples (50 µg and 100 µg of protein from membrane fractions of HEK-rCRFR1 cells and HEK-mCRFR2β cells, respectively) were reacted with 10 µl of disuccinimidyl suberate (1.5 mM in dimethylsulfoxide, 23°C, 20 min) after incubation with ligand ( $V = 300$  µl, 100,000 cpm, 1 hr, 23°C). The reaction was terminated by the addition of 1.0 ml of ice-cold buffer (10 mM Tris/Cl, 1 ml EDTA, pH 7.0, 4°C). In some experiments, the chemically cross-linked receptor was deglycosylated with PNGase (New England Biolabs, Schwalbach). Samples were then heated (100°C, 5 min) and subjected to SDS PAGE. Autoradiography was carried out on a BAS-IP NP 2040P imaging plate. Radioactivity was monitored with a Fujix BAS 2000 scanner (Raytest, Straubenhardt). Gel documentation was accomplished with the program TINA (Raytest).

#### Example 4: Determination of cAMP stimulation

HEK-rCRFR1 cells or HEK-mCRFR2β cells were incubated with different CRF agonists in the presence or absence of 1 µM or 10 nM antagonist, or CRF antagonist ( $c = 1$  µM) alone. After removal of the medium, cells were lysed with aqueous 6% trichloroacetic acid (5 min, 100°C) (Rühmann, A., A. K. E. Köpke, F. M. Dautzenberg, and J. Spiess, *Proc. Natl. Acad. Sci. USA* 93:10609-10613, 1996). The cell lysates were stored at -70°C until assayed with a RIA kit (Amersham, Little Chalfont). Data analysis was achieved with the sigmoidal dose-response curve fitting program ALLFIT. Statistical significance was determined across groups with ANOVA, and significant differences between groups were determined by post hoc comparison using the Dunn test.

#### Example 5: Displacement of [ $^{125}$ I-Tyr $^0$ ]oCRF or [ $^{125}$ I-Tyr $^0$ ]Svq from recombinant rCRFR1 or mCRFR2β by CRF analogs

Membrane homogenates of human embryonic kidney (HEK) 293 cells stably transfected with cDNA coding for rat CRF receptor, type 1 (rCRFR1) or mouse CRF receptor, type 2β (mCRFR2β) were prepared according to standard protocols (see, e.g., Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd. Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989; Ausubel et al., *Current Protocols in Molecular Biology*, Green Publishing Associates and Wiley Interscience, NY, 1989). The specific binding of [ $^{125}$ I-Tyr $^0$ ]oCRF to membranes of HEK-rCRFR1 cells

was found to be 93% when the radioligand was displaced by oCRF. In analogous displacement experiments with Svg, the specific binding of [ $^{125}$ I-Tyr $^0$ ]Svg to membranes of HEK-mCRFR2 $\beta$  cells was determined to be 94%. No specific binding of the two radioactively labeled CRF analogs to membranes of nontransfected HEK 293 cells could be observed. These data could be confirmed when [ $^{125}$ I-Tyr $^0$ ]oCRF and [ $^{125}$ I-Tyr $^0$ ]Svg were chemically cross-linked to rCRFR1 and mCRFR2 $\beta$ , respectively. The molecular weight of both cross-linked receptors was 66,000. After deglycosylation with PNGase, molecular weights of 43,000 and 41,000 were found for crosslinked mCRFR2 $\beta$  and rCRFR1, respectively (Fig. 2), which are in agreement with the molecular weight predicted on the basis of DNA data (Perrin, M. H., C. J. Donaldson, R. Chen, K. A. Lewis, and W. Vale, *Endocrinology* 133:3058-3061, 1993; Kishimoto, T., R. V. Pearce II, C. R. Lin, and M. G. Rosenfeld, *Proc. Natl. Acad. Sci. USA* 92:1108-1112, 1995). The difference of 2,000 between the molecular weights of rCRFR1 and mCRFR2 $\beta$  is probably due to the longer amino acid sequence of mCRFR2 $\beta$ . No chemical cross-links could be observed with either radioligand to nontransfected HEK 293 cells.

As expected for the CRF peptide agonists (Dautzenberg, F. M., K. Dietrich, M. R. Palchaudhuri, and J. Spiess, *J. Neurochem.* 69:1640-1649, 1997; Donaldson, C. J., S. W. Sutton, M. H. Perrin, A. Z. Corrigan, K. A. Lewis, J. E. Rivier, J. M. Vaughan, and W. W. Vale, *Endocrinology* 137:2167-2170, 1996; Gottowik, J., V. Goetschy, S. Henriot, E. Kitis, E. Fluhman, R. G. Clerc, J. L. Moreau, F. J. Monsma, and G. J. Kilpatrick, *Neuropharmacol.* 36:1439-1446, 1997), oCRF and Svg exhibited similar high-affinity binding to rCRFR1 (oCRF:  $K_d = 0.6 \pm 0.1$  nM, Svg:  $K_d = 0.7 \pm 0.1$  nM), but differed significantly in their binding to mCRFR2 $\beta$  (oCRF:  $K_d = 162.4 \pm 37.6$  nM, Svg:  $K_d = 4.5 \pm 0.6$  nM) (Table 1, Fig. 3).

For the binding of the CRF antagonists, ( $\alpha$ -helical CRF $_{(9-41)}$  and [DPhe $^{12}$ , Nle $^{21,38}$ ]h/rCRF $_{(12-41)}$  described earlier (Gulyas, J., C. Rivier, M. Perrin, S. C. Koerber, S. Sutton, A. Corrigan, S. L. Lahrachi, A. G. Craig, W. Vale, and J. Rivier, *Proc. Natl. Acad. Sci. USA* 92:10575-10579, 1995) to rCRFR1,  $K_d$  values of  $60.3 \pm 10.6$  nM and  $46.4 \pm 9.4$  nM were obtained, respectively. The antagonist astressin (Gulyas, J., C. Rivier, M. Perrin, S. C. Koerber, S. Sutton, A. Corrigan, S. L. Lahrachi, A. G. Craig, W.

Vale, and J. Rivier, *Proc. Natl. Acad. Sci. USA* 92:10575-10579, 1995), cyclo(30-33)[DPhe<sup>12</sup>, Nle<sup>21,38</sup>, Glu<sup>30</sup>, Lys<sup>33</sup>]h/rCRF<sub>(12-41)</sub>, was found to bind nonselectively with similar affinity to rCRFR1 ( $K_d = 5.7 \pm 1.6$  nM) and mCRFR2 $\beta$  ( $K_d = 4.0 \pm 2.3$  nM), whereas  $\alpha$ -helical CRF<sub>(9-41)</sub> and [DPhe<sup>12</sup>, Nle<sup>21,38</sup>]h/rCRF<sub>(12-41)</sub> showed moderate selectivity for binding to mCRFR2 $\beta$  with  $K_d$  values of  $6.4 \pm 0.9$  nM and  $17.7 \pm 2.2$  nM, respectively (Table 1). [DPhe<sup>12</sup>]oCRF<sub>(12-41)</sub> based on the amino acid sequence of oCRF showed low-affinity binding to rCRFR1 and mCRFR2 $\beta$  with  $K_d$  values of  $290.2 \pm 74.7$  nM and  $153.8 \pm 26.8$  nM, respectively (Table 1, Fig. 3).

The truncated Ucn analogs [DPhe<sup>11</sup>]rUcn<sub>(11-40)</sub>, [DPhe<sup>11</sup>, Glu<sup>12</sup>]rUcn<sub>(11-40)</sub>, [DLeu<sup>11</sup>, Glu<sup>12</sup>]rUcn<sub>(11-40)</sub>, and cyclo(29-32)[DPhe<sup>11</sup>, Glu<sup>29</sup>, Lys<sup>32</sup>]rUcn<sub>(11-40)</sub> exhibited moderate binding affinity to rCRFR1 with  $K_d$  values of  $33.0 \pm 5.9$  nM,  $68.2 \pm 20.5$  nM,  $91.1 \pm 21.2$  nM, and  $47.1 \pm 8.9$  nM, respectively, and revealed little preference for binding to mCRFR2 $\beta$  with  $K_d$  values of  $5.2 \pm 1.5$  nM,  $9.5 \pm 2.0$  nM,  $27.9 \pm 3.4$  nM, and  $22.4 \pm 4.6$  nM, respectively (Table 1, Fig. 3).

The Svg-derived peptides [DLeu<sup>11</sup>]Svg<sub>(11-40)</sub>, Svg<sub>(11-40)</sub>, [DPhe<sup>11</sup>]Svg<sub>(11-40)</sub>, and [DPhe<sup>11</sup>, His<sup>12</sup>]Svg<sub>(11-40)</sub> showed low-affinity binding to rCRFR1 with  $K_d$  values of  $1670.0 \pm 500.0$  nM,  $831.2 \pm 668.8$  nM,  $237.3 \pm 27.7$  nM, and  $153.6 \pm 33.5$  nM, respectively, but high-affinity binding to mCRFR2 $\beta$  with  $K_d$  values of  $20.9 \pm 4.1$  nM,  $15.4 \pm 2.5$  nM,  $3.5 \pm 0.2$  nM, and  $1.4 \pm 0.4$  nM, respectively (Table 1). Thus, [DPhe<sup>11</sup>, His<sup>12</sup>]Svg<sub>(11-40)</sub>, [DLeu<sup>11</sup>]Svg<sub>(11-40)</sub>, [DPhe<sup>11</sup>]Svg<sub>(11-40)</sub>, and Svg<sub>(11-40)</sub> bound with a 77-, 56-, 47-, and 38-fold higher selectivity to mCRFR2 $\beta$  than astressin, respectively.

ANOVA indicated statistically significant differences in high-affinity binding,  $F(13,41) = 13.17$   $p = 0.0001$ , of the CRF peptides (compounds 1-14) to cell membranes of HEK-rCRFR cells (Table 1). Post hoc comparison demonstrated a significantly lower binding affinity of [DLeu<sup>11</sup>]Svg<sub>(11-40)</sub> (compound 13) and Svg<sub>(11-40)</sub> (compound 14) to cell membranes when compared to compounds 1-5, and 7-11 ( $p = 0.0001$ ) (Table 1). Statistically significant differences in high-affinity binding,  $F(13,36) = 20.34$   $p = 0.0001$ , of oCRF (compound 1) and [DPhe<sup>12</sup>]oCRF<sub>(12-41)</sub> (compound 6) to cell membranes of HEK-mCRFR2 $\beta$  cells were observed. Post hoc

comparison demonstrated a significantly lower binding affinity of oCRF (compound 1) and [DPhe<sup>12</sup>]oCRF<sub>(12-41)</sub> (compound 6) to cell membranes when compared to compounds 2-5 and compounds 7-14 ( $p = 0.0001$ ) (Table 1).

Thus, in comparison to astressin, the most potent CRF antagonist described to date (Gulyas, J., C. Rivier, M. Perrin, S. C. Koerber, S. Sutton, A. Corrigan, S. L. Lahrchi, A. G. Craig, W. Vale, and J. Rivier, *Proc. Natl. Acad. Sci. USA* **92**:10575-10579, 1995), the intrinsic activity of [DPhe<sup>11</sup>, His<sup>12</sup>]Sv<sub>(11-40)</sub> was not significantly different in experiments with HEK-rCRFR1 or HEK-mCRFR2 $\beta$  cells. However, the inhibitory potency of [DPhe<sup>11</sup>, His<sup>12</sup>]Sv<sub>(11-40)</sub> towards rCRFR1 was found to be 15% of the potency of astressin. This difference was determined to be significant. In contrast, no significant difference between the inhibitory potencies of astressin and [DPhe<sup>11</sup>, His<sup>12</sup>]Sv<sub>(11-40)</sub> was observed, when HEK-mCRFR2 $\beta$  cells were tested (Table 2). The difference between astressin and [DPhe<sup>11</sup>, His<sup>12</sup>]Sv<sub>(11-40)</sub> was even more pronounced in binding experiments (Table 1) which demonstrated that [DPhe<sup>11</sup>, His<sup>12</sup>]Sv<sub>(11-40)</sub> exhibited in contrast to astressin selective binding to mCRFR2 $\beta$ . On the basis of ligand comparisons, [DPhe<sup>11</sup>, His<sup>12</sup>]Sv<sub>(11-40)</sub> was thus demonstrated to be a selective, mCRFR2 $\beta$ -directed CRF antagonist with low intrinsic activities directed towards rCRFR1 and mCRFR2 $\beta$ .

In contrast to CRFR2, mammalian CRFR1 has been reported to be nonselective for CRF and CRF-like peptides including the structurally related 40-amino acid peptides Sv<sub>g</sub> and Ucn (Vita, N., P. Laurent, S. Lefort, P. Chalon, J.-M. Lelias, M. Kaghad, G. Le Fur, D. Caput, and P. Ferrara, *FEBS Lett.* **335**:1-5, 1993; Dautzenberg, F. M., K. Dietrich, M. R. Palchaudhuri, and J. Spiess, *J. Neurochem.* **69**:1640-1649, 1997; Vaughan, J., C. Donaldson, J. Bittencourt, M. H. Perrin, K. Lewis, S. Sutton, R. Chan, A. V. Turnbull, D. Lovejoy, C. Rivier, J. Rivier, P. E. Sawchenko, and W. Vale, *Nature (London)* **378**:287-292, 1995; Fisher, L., C. Rivier, J. Rivier, and M. Brown, *Endocrinology* **129**:1312-1316, 1991; Donaldson, C. J., S. W. Sutton, M. H. Perrin, A. Z. Corrigan, K. A. Lewis, J. E. Rivier, J. M. Vaughan, and W. W. Vale, *Endocrinology* **137**:2167-2170, 1996). Experimental data available thus far do not show significant pharmacological differences between mammalian CRFR2 $\alpha$  and CRFR2 $\beta$  (Fisher, L., C. Rivier, J. Rivier, and M. Brown, *Endocrinology* **129**:1312-1316, 1991; Donaldson, C.



J., S. W. Sutton, M. H. Perrin, A. Z. Corrigan, K. A. Lewis, J. E. Rivier, J. M. Vaughan, and W. W. Vale, *Endocrinology* **137**:2167-2170 (1996). On this basis, it is expected that [DPhe<sup>11</sup>, His<sup>12</sup>]SvG<sub>(11-40)</sub> inhibits CRFR2 $\alpha$  similarly as CRFR2 $\beta$ . Indeed, results obtained from in vivo experiments with 3ALB/c mice showed that [DPhe<sup>11</sup>, His<sup>12</sup>]SvG<sub>(11-40)</sub> inhibited CRF-mediated behavioral effects in the lateral septum (J. Radulovic, A. Rühmann, T. Liepold and J. Spiess, *J. Neurosci.* **19** (1999), 5016-5025; D.T. Chalmers, T.W. Lovenberg and E. B. DeSouza, *J. Neurosci.* **15** (1995), 6340-6350) an area in the brain which exclusively expresses CRF2 $\alpha$ -mRNA.

#### Example 6: cAMP stimulation

The peptide agonists oCRF and Svg exhibited high potency to increase cAMP accumulation in HEK-rCRFR1 cells with EC<sub>50</sub> values of  $0.41 \pm 0.08$  nM and  $0.19 \pm 0.05$  nM, respectively, but differed significantly in their potencies to stimulate cAMP production in HEK-mCRFR2 $\beta$  cells with EC<sub>50</sub> values of  $11.79 \pm 1.96$  nM and  $0.23 \pm 0.05$  nM, respectively.

The CRF antagonists (compounds 3-14, Table 2, Fig. 4) mentioned above were tested for their ability to enhance or inhibit oCRF- and Svg-stimulated cAMP production in transfected HEK 293 cells expressing rCRFR1 (HEK-CRFR1 cells) and mCRFR2 $\beta$  (HEK-mCRFR2 $\beta$  cells), respectively. Intrinsic activities were measured at peptide concentrations generating maximal formation of cAMP in HEK-rCRFR1 or HEK-mCRFR2 $\beta$  cells. The intrinsic activities of CRF antagonists tested by their effect at a concentration of 1  $\mu$ M on HEK-rCRFR1 cells ranged from 4-23% of the intrinsic activity of oCRF (compound 1) tested at a concentration of 1 nM. The intrinsic activities of the antagonists tested under equivalent conditions with HEK-mCRFR2 $\beta$  cells were 0.4-0.9% of the intrinsic activity of Svg (compound 2) (Table 2, Fig. 4).

ANOVA indicated statistically significant differences in intrinsic activity,  $F(12,50) = 11.68$ ,  $p = 0.0001$ , of compounds 3-14 to stimulate cAMP production in HEK-rCRFR1 cells. Post hoc comparison demonstrated a significantly higher intrinsic activity of compounds 8, 9, and 13 when compared to compounds 5, 6, 7, 11, and 12 ( $p = 0.001$ ). Compounds 4 and 14 also significantly increased cAMP production in HEK-rCRFR1 cells when compared to the basal level of cAMP in the same cells ( $p = 0.001$ ) (Table 2). ANOVA indicated no statistically significant differences in

intrinsic activity of compounds **3-14** to stimulate cAMP production in HEK-mCRFR2 $\beta$  cells. Compound **11** exhibited the lowest intrinsic activity of all tested CRF antagonists in experiments with either recombinant system, HEK-rCRFR1 cells and HEK-mCRFR2 $\beta$  cells (Table 2).

The rank order of potencies for the CRF related peptide antagonists to suppress oCRF-induced cAMP-accumulation in HEK-rCRFR1 cells was as follows: astressin (compound **3**) and [DPhe<sup>11</sup>]Ucn<sub>(11-40)</sub> (compound **7**) > [DPhe<sup>12</sup>, Nle<sup>21,38</sup>]h/rCRF<sub>(12-41)</sub> (compound **5**) and [DPhe<sup>11</sup>, Glu<sup>12</sup>]rUcn<sub>(11-40)</sub> (compound **8**) > [DLeu<sup>11</sup>, Glu<sup>12</sup>]rUcn<sub>(11-40)</sub> (compound **9**) and  $\alpha$ -helical CRF<sub>(9-41)</sub> (compound **4**) > [DPhe<sup>11</sup>, His<sup>12</sup>]Sv<sub>(11-40)</sub> (compound **11**), [DPhe<sup>11</sup>]Sv<sub>(11-40)</sub> (compound **12**), Sv<sub>(11-40)</sub> (compound **14**), and cyclo(29-32)[DPhe<sup>11</sup>, Glu<sup>29</sup>, Lys<sup>32</sup>]rUcn<sub>(11-40)</sub> (compound **10**) > [DPhe<sup>12</sup>]oCRF<sub>(12-41)</sub> (compound **6**) and [DLeu<sup>11</sup>]Sv<sub>(11-40)</sub> (compound **13**). In contrast, the following pharmacological profile was obtained for the inhibition of Svg-stimulated cAMP production in HEK-mCRFR2 $\beta$  cells by CRF antagonists: [DPhe<sup>11</sup>, His<sup>12</sup>]Sv<sub>(11-40)</sub> (compound **11**) > astressin (compound **3**), [DPhe<sup>11</sup>]rUcn<sub>(11-40)</sub> (compound **7**), [DPhe<sup>11</sup>, Glu<sup>12</sup>]rUcn<sub>(11-40)</sub> (compound **8**), and  $\alpha$ -helical CRF<sub>(9-41)</sub> (compound **4**) > [DPhe<sup>11</sup>]Sv<sub>(11-40)</sub> (compound **12**), [DLeu<sup>11</sup>]Sv<sub>(11-40)</sub> (compound **13**), and Sv<sub>(11-40)</sub> (compound **14**) > [DLeu<sup>11</sup>, Glu<sup>12</sup>]rUcn<sub>(11-40)</sub> (compound **9**) > [DPhe<sup>12</sup>, Nle<sup>21,38</sup>]h/rCRF<sub>(12-41)</sub> (compound **5**), cyclo(29-32)[DPhe<sup>11</sup>, Glu<sup>29</sup>, Lys<sup>32</sup>]rUcn<sub>(11-40)</sub> (compound **10**), and [DPhe<sup>12</sup>]oCRF<sub>(12-41)</sub> (compound **6**).

ANOVA indicated statistically significant differences in potency,  $F(12,39) = 7.93$ ,  $p = 0.0001$ , of compounds **3-14** to inhibit oCRF-stimulated cAMP production in HEK-rCRFR1 cells. Post hoc comparison demonstrated a significantly higher potency of compounds **3** and **7** when compared to compounds **6** ( $p = 0.0001$ ) and compounds **10-14** ( $p = 0.0001$ ). A significantly higher potency was also observed for compound **5** when compared to compounds **6** ( $p = 0.001$ ) and **13** ( $p = 0.0001$ ).

ANOVA indicated statistically significant differences in potency,  $F(12,65) = 6.34$ ,  $p = 0.0001$ , of compounds **3-14** to inhibit Svg-stimulated cAMP production in HEK-mCRFR2 $\beta$  cells. Post hoc comparison demonstrated a significantly higher potency of compound **11** when compared to compounds **2** and **4** ( $p = 0.001$ ) or compounds **5**, **6**,

9, 10, and 13 ( $p = 0.0001$ ).

**Example 7: Synthesis of 4-(1-azi-2,2,2-trifluoroethyl)benzoic acid**

4-(1-azi-2,2,2-trifluoroethyl)benzoic acid was synthesized as described in PCT/EP96/05011.

**Example 8: Analysis of CRFR2-selective antagonists suitable for radioactive labelling and photoaffinity labelling experiments**

Corticotropin-releasing factor (CRF) receptor, type 2 $\beta$  (CRFR2 $\beta$ )-selective antagonists based on the truncated amino acid sequence of sauvagine (Svg) were synthesized and characterized. The N-terminal amino acid Leu<sup>11</sup> in Svg (11-40) was substituted by either tyrosine or a phenyldiazirine, the 4-(1-azi-2,2,2-trifluoroethyl)benzoyl (ATB) group, for radioactive labelling or photoaffinity labelling experiments, respectively. To further increase the binding affinity of the ligands to membrane homogenates of human embryonic kidney (HEK) cells permanently transfected with cDNA coding for rat CRFR1 (rCRFR1) or mouse CRFR2 $\beta$  (mCRFR2 $\beta$ ), Glu<sup>12</sup> was substituted by histidine.

The binding affinity of the compounds to rCRFR1 and mCRFR2 $\beta$  and the potency of the ligands to produce cAMP accumulation (agonistic activity) or inhibit oCRF- (rCRFR1) or Svg-(mCRFR2 $\beta$ ) stimulated cAMP production (antagonistic activity) in transfected cells were compared with the binding affinity and potency of antisauvagine-30 {[DPhe<sup>11</sup>, His<sup>12</sup>]Svg(11-40)} (compound 11), astressin {cyclo(30-33)[DPhe<sup>12</sup>, Nle<sup>21,38</sup>, Glu<sup>30</sup>, Lys<sup>33</sup>]h/rCRF(12-41)} (compound 3) and the photoactivatable astressin analogs ATB-cyclo(30-33)[Nle<sup>21,38</sup>, Glu<sup>30</sup>, Ala<sup>32</sup>, Lys<sup>33</sup>]h/rCRF(13-41) (compound 15) and ATB-cyclo(30-33)[Nle<sup>21,38</sup>, Glu<sup>30</sup>, Tyr<sup>32</sup>, Lys<sup>33</sup>]h/rCRF(13-41) (compound 16).

Substitution of DPhe<sup>11</sup> by the phenyldiazirine moiety in ATB-[His<sup>12</sup>]Svg(12-40) (compound 17) did not significantly change the binding affinity, ligand selectivity, and potency of this ligand to CRFR1 and mCRFR2 $\beta$  when compared with antisauvagine-30 (compound 11) (Table 3 and 4). Similar results could be observed for ATB-cyclo(30-33)[(Nle<sup>21,38</sup>, Glu<sup>30</sup>, Ala<sup>32</sup>, Lys<sup>33</sup>)h/rCRF(13-41) (compound 15) when compared with astressin (compound 3) (Table 3 and 4).

Substitution of DPhe<sup>11</sup> by tyrosine in [Tyr<sup>11</sup>, His<sup>12</sup>]Svg(11-40) (compound 18) or

[Tyr<sup>11</sup>]Svg(11-40) (compound 19) decreased the binding affinity of these compounds to rCRFR1 or mCRFR2 $\beta$  by 1.4 to 5.9-fold when compared to antisauvagine-30 (compound 11) or [DPhe<sup>11</sup>]Svg(11-40) (compound 12), respectively, without changing preferable binding to mCRFR2 $\beta$ . Further N-terminal truncation of the amino acid sequence Svg(11-40) by one amino acid and substitution of Glu<sup>12</sup> by tyrosine completely abolished high-affinity binding of [Tyr<sup>12</sup>]Svg(12-40) (compound 20) to mCRFR2 $\beta$  (Table 3).

TABLE I

Binding constants ( $K_d$ , [nM]) found for different CRF-related agonists and antagonists when bound to recombinant rCRFR1 with [125I-Tyr<sup>0</sup>]oCRF as competitive ligand or recombinant mCRFR2 $\beta$  with [125I-Tyr<sup>0</sup>]Svg as competitive ligand.

No.	peptides	[125I-Tyr <sup>0</sup> ]oCRF $K_d$ (rCRFR1), [nM]	[125I-Tyr <sup>0</sup> ]Svg $K_d$ (mCRFR2 $\beta$ ), [nM]	P	Selectivity <sup>c</sup>
1	oCRF	0.6 $\pm$ 0.1	162.4 $\pm$ 37.6 <sup>e</sup>	[*]	0.002
2	Svg	0.7 $\pm$ 0.1	4.5 $\pm$ 0.6	[**]	0.109
3	astressin	5.7 $\pm$ 1.6	4.0 $\pm$ 2.3	N.S.	1.00
4	$\alpha$ -helical CRF(9-41)	60.3 $\pm$ 10.6	6.4 $\pm$ 0.9	[**]	6.61
5	[DPhe <sup>12</sup> , Nle <sup>21,30</sup> ]rCRF(12-41)	46.4 $\pm$ 9.4	17.7 $\pm$ 2.2	[*]	1.84
6	[DPhe <sup>12</sup> ]oCRF(12-41)	290.2 $\pm$ 74.7	153.8 $\pm$ 26.8 <sup>d</sup>	N.S.	1.32
7	[DPhe <sup>11</sup> ]rUcn(11-40)	33.0 $\pm$ 5.9	5.2 $\pm$ 1.5	[**]	4.45
8	[DPhe <sup>11</sup> , Glu <sup>12</sup> ]rUcn(11-40)	68.2 $\pm$ 20.5	9.5 $\pm$ 2.0	[*]	5.04
9	[DLeu <sup>11</sup> , Glu <sup>12</sup> ]rUcn(11-40)	91.1 $\pm$ 21.2	27.9 $\pm$ 3.4	[*]	2.29
10	cyclo(29-32) [DPhe <sup>11</sup> , Glu <sup>29</sup> , Lys <sup>32</sup> ]rUcn(11-40)	47.1 $\pm$ 8.9	22.4 $\pm$ 4.6	N.S.	1.48
11	[DPhe <sup>11</sup> , His <sup>12</sup> ]Svg(11-40)	153.6 $\pm$ 33.5	1.4 $\pm$ 0.4	[**]	76.99
12	[DPhe <sup>11</sup> ]Svg(11-40)	237.3 $\pm$ 27.7	3.5 $\pm$ 0.2	[*]	47.58
13	[DLeu <sup>11</sup> ]Svg(11-40)	1670.0 $\pm$ 500.0 <sup>a</sup>	20.9 $\pm$ 4.1	[**]	56.07
14	Svg(11-40)	831.2 $\pm$ 668.8 <sup>b</sup>	15.4 $\pm$ 2.5	N.S.	37.88

Statistically significant differences between the  $K_d$  values of the peptides: <sup>a</sup>,  $p \leq 0.0001$  vs. 1-12, 14, <sup>b</sup>,  $p \leq 0.0001$  vs. 1-5, 7-11, 13, <sup>c</sup>,  $p \leq 0.0001$  vs. 2-5, 7-14, <sup>d</sup>,  $P$  values of unpaired Student's  $t$  test obtained by comparing the  $K_d$  value with the  $K_d$  value of each peptide. <sup>\*\*\*</sup>,  $p \leq 0.001$ , <sup>\*\*</sup>,  $0.01 \geq p > 0.001$ , <sup>\*</sup>,  $0.05 \geq p > 0.01$ , N.S., not significant. <sup>e</sup>, Selectivity was calculated according to the equation: Selectivity =  $K_d$ (rCRFR1) (agonist/antagonist)/ $K_d$ (rCRFR1) (astressin)  $\times$   $K_d$ (mCRFR2 $\beta$ ) (astressin)/ $K_d$ (mCRFR2 $\beta$ ) (agonist/antagonist).

TABLE 2

Potency of 1  $\mu$ M CRF antagonist to stimulate cAMP production in transfected HEK 293 cells (%IA, intrinsic activity). Efficacy of 1  $\mu$ M (rCRFR1) or 10 nM (mCRFR2 $\beta$ ) CRF antagonist to inhibit cAMP production stimulated by oCRF (rCRFR1) or Svg (mCRFR2 $\beta$ ) (1 nM) in transfected HEK 293 cells (relative *in vitro* potency).

No.	peptides	rCRFR1 %IA	relative <i>in vitro</i> potency	mCRFR2 $\beta$ %IA	relative <i>in vitro</i> potency
1	oCRF	1.00	1.00	-	-
2	Svg	-	-	1.00	1.00
3	astressin	0.10 $\pm$ 0.02	0.11 $\pm$ 0.03 <sup>f</sup>	0.004 $\pm$ 0.001	0.57 $\pm$ 0.04
4	$\alpha$ -helical CRF(9-41)	0.16 $\pm$ 0.02 <sup>a</sup>	0.58 $\pm$ 0.05	0.007 $\pm$ 0.004	0.67 $\pm$ 0.02
5	[DPhel <sup>12</sup> , Nle <sup>21,38</sup> ]h/rCRF(12-41)	0.06 $\pm$ 0.01	0.33 $\pm$ 0.08 <sup>h,i</sup>	0.007 $\pm$ 0.002	0.87 $\pm$ 0.08 <sup>j</sup>
6	[DPhel <sup>12</sup> ]oCRF(12-41)	0.05 $\pm$ 0.01	0.89 $\pm$ 0.07	0.008 $\pm$ 0.003	0.92 $\pm$ 0.07 <sup>k</sup>
7	[DPhel <sup>11</sup> ]rUen(11-40)	0.07 $\pm$ 0.01	0.18 $\pm$ 0.03 <sup>g</sup>	0.011 $\pm$ 0.003	0.57 $\pm$ 0.06
8	[DPhel <sup>11</sup> , Glu <sup>12</sup> ]rUen(11-40)	0.22 $\pm$ 0.05 <sup>b</sup>	0.42 $\pm$ 0.11	0.004 $\pm$ 0.001	0.67 $\pm$ 0.02
9	[DLeu <sup>11</sup> , Glu <sup>12</sup> ]rUen(11-40)	0.23 $\pm$ 0.04 <sup>c</sup>	0.56 $\pm$ 0.05	0.009 $\pm$ 0.002	0.81 $\pm$ 0.06
10	cyclo(29-32)[DPhel <sup>11</sup> , Glu <sup>29</sup> , Lys <sup>32</sup> ]rUen(11-40)	0.10 $\pm$ 0.06	0.78 $\pm$ 0.10	0.005 $\pm$ 0.001	0.89 $\pm$ 0.01
11	[DPhel <sup>11</sup> , His <sup>12</sup> ]Svg(11-40)	0.04 $\pm$ 0.01	0.73 $\pm$ 0.07	0.004 $\pm$ 0.001	0.42 $\pm$ 0.02 <sup>l,m</sup>
12	[DPhel <sup>11</sup> ]Svg(11-40)	0.07 $\pm$ 0.01	0.75 $\pm$ 0.13	0.005 $\pm$ 0.001	0.71 $\pm$ 0.04
13	[DLeu <sup>11</sup> ]Svg(11-40)	0.22 $\pm$ 0.04 <sup>d</sup>	0.92 $\pm$ 0.16	0.008 $\pm$ 0.002	0.75 $\pm$ 0.06
14	Svg(11-40)	0.14 $\pm$ 0.02 <sup>e</sup>	0.76 $\pm$ 0.16	0.005 $\pm$ 0.001	0.76 $\pm$ 0.02
	basal	0.01 $\pm$ 0.003	-	0.004 $\pm$ 0.001	-

Statistically significant differences between the intrinsic activities of the peptides: <sup>a</sup>, 0.001  $\geq p > 0.0001$  vs. 15; <sup>b</sup>, <sup>c</sup>, <sup>d</sup>, <sup>e</sup>, <sup>f</sup>, <sup>g</sup>, <sup>h</sup>, <sup>i</sup>, <sup>j</sup>, <sup>k</sup>, <sup>l</sup>, <sup>m</sup>, <sup>n</sup>, <sup>o</sup>, <sup>p</sup>, <sup>q</sup>, <sup>r</sup>, <sup>s</sup>, <sup>t</sup>, <sup>u</sup>, <sup>v</sup>, <sup>w</sup>, <sup>x</sup>, <sup>y</sup>, <sup>z</sup>, <sup>aa</sup>, <sup>ab</sup>, <sup>ac</sup>, <sup>ad</sup>, <sup>ae</sup>, <sup>af</sup>, <sup>ag</sup>, <sup>ah</sup>, <sup>ai</sup>, <sup>aj</sup>, <sup>ak</sup>, <sup>al</sup>, <sup>am</sup>, <sup>an</sup>, <sup>ao</sup>, <sup>ap</sup>, <sup>aq</sup>, <sup>ar</sup>, <sup>as</sup>, <sup>at</sup>, <sup>au</sup>, <sup>av</sup>, <sup>aw</sup>, <sup>ax</sup>, <sup>ay</sup>, <sup>az</sup>, <sup>ba</sup>, <sup>bb</sup>, <sup>bc</sup>, <sup>bd</sup>, <sup>be</sup>, <sup>bf</sup>, <sup>bg</sup>, <sup>bh</sup>, <sup>bi</sup>, <sup>bj</sup>, <sup>bk</sup>, <sup>bl</sup>, <sup>bm</sup>, <sup>bn</sup>, <sup>bo</sup>, <sup>bp</sup>, <sup>bq</sup>, <sup>br</sup>, <sup>bs</sup>, <sup>bt</sup>, <sup>bu</sup>, <sup>bv</sup>, <sup>bw</sup>, <sup>bx</sup>, <sup>by</sup>, <sup>bz</sup>, <sup>ca</sup>, <sup>cb</sup>, <sup>cc</sup>, <sup>cd</sup>, <sup>ce</sup>, <sup>cf</sup>, <sup>cg</sup>, <sup>ch</sup>, <sup>ci</sup>, <sup>cj</sup>, <sup>ck</sup>, <sup>cl</sup>, <sup>cm</sup>, <sup>cn</sup>, <sup>co</sup>, <sup>cp</sup>, <sup>cq</sup>, <sup>cr</sup>, <sup>cs</sup>, <sup>ct</sup>, <sup>cu</sup>, <sup>cv</sup>, <sup>cw</sup>, <sup>cx</sup>, <sup>cy</sup>, <sup>cz</sup>, <sup>da</sup>, <sup>db</sup>, <sup>dc</sup>, <sup>dd</sup>, <sup>de</sup>, <sup>df</sup>, <sup>dg</sup>, <sup>dh</sup>, <sup>di</sup>, <sup>dj</sup>, <sup>dk</sup>, <sup>dl</sup>, <sup>dm</sup>, <sup>dn</sup>, <sup>do</sup>, <sup>dp</sup>, <sup>dq</sup>, <sup>dr</sup>, <sup>ds</sup>, <sup>dt</sup>, <sup>du</sup>, <sup>dv</sup>, <sup>dw</sup>, <sup>dx</sup>, <sup>dy</sup>, <sup>dz</sup>, <sup>ea</sup>, <sup>eb</sup>, <sup>ec</sup>, <sup>ed</sup>, <sup>ee</sup>, <sup>ef</sup>, <sup>eg</sup>, <sup>eh</sup>, <sup>ei</sup>, <sup>ej</sup>, <sup>ek</sup>, <sup>el</sup>, <sup>em</sup>, <sup>en</sup>, <sup>eo</sup>, <sup>ep</sup>, <sup>eq</sup>, <sup>er</sup>, <sup>es</sup>, <sup>et</sup>, <sup>eu</sup>, <sup>ev</sup>, <sup>ew</sup>, <sup>ex</sup>, <sup>ey</sup>, <sup>ez</sup>, <sup>fa</sup>, <sup>fb</sup>, <sup>fc</sup>, <sup>fd</sup>, <sup>fe</sup>, <sup>ff</sup>, <sup>fg</sup>, <sup>fh</sup>, <sup>fi</sup>, <sup>fj</sup>, <sup>fk</sup>, <sup>fl</sup>, <sup>fm</sup>, <sup>fn</sup>, <sup>fo</sup>, <sup>fp</sup>, <sup>fq</sup>, <sup>fr</sup>, <sup>fs</sup>, <sup>ft</sup>, <sup>fu</sup>, <sup>fv</sup>, <sup>fw</sup>, <sup>fx</sup>, <sup>fy</sup>, <sup>fz</sup>, <sup>ga</sup>, <sup>gb</sup>, <sup>gc</sup>, <sup>gd</sup>, <sup>ge</sup>, <sup>gf</sup>, <sup>gg</sup>, <sup>gh</sup>, <sup>gi</sup>, <sup>gj</sup>, <sup>gk</sup>, <sup>gl</sup>, <sup>gm</sup>, <sup>gn</sup>, <sup>go</sup>, <sup>gp</sup>, <sup>gq</sup>, <sup>gr</sup>, <sup>gs</sup>, <sup>gt</sup>, <sup>gu</sup>, <sup>gv</sup>, <sup>gw</sup>, <sup>gx</sup>, <sup>gy</sup>, <sup>gz</sup>, <sup>ha</sup>, <sup>hb</sup>, <sup>hc</sup>, <sup>hd</sup>, <sup>he</sup>, <sup>hf</sup>, <sup>hg</sup>, <sup>hh</sup>, <sup>hi</sup>, <sup>hj</sup>, <sup>hk</sup>, <sup>hl</sup>, <sup>hm</sup>, <sup>hn</sup>, <sup>ho</sup>, <sup>hp</sup>, <sup>hq</sup>, <sup>hr</sup>, <sup>hs</sup>, <sup>ht</sup>, <sup>hu</sup>, <sup>hv</sup>, <sup>hw</sup>, <sup>hx</sup>, <sup>hy</sup>, <sup>hz</sup>, <sup>ia</sup>, <sup>ib</sup>, <sup>ic</sup>, <sup>id</sup>, <sup>ie</sup>, <sup>if</sup>, <sup>ig</sup>, <sup>ih</sup>, <sup>ii</sup>, <sup>ij</sup>, <sup>ik</sup>, <sup>il</sup>, <sup>im</sup>, <sup>in</sup>, <sup>io</sup>, <sup>ip</sup>, <sup>iq</sup>, <sup>ir</sup>, <sup>is</sup>, <sup>it</sup>, <sup>iu</sup>, <sup>iv</sup>, <sup>iw</sup>, <sup>ix</sup>, <sup>iy</sup>, <sup>iz</sup>, <sup>ja</sup>, <sup>jb</sup>, <sup>jc</sup>, <sup>jd</sup>, <sup>je</sup>, <sup>jf</sup>, <sup>jh</sup>, <sup>ji</sup>, <sup>jj</sup>, <sup>jk</sup>, <sup>jl</sup>, <sup>jm</sup>, <sup>jn</sup>, <sup>jo</sup>, <sup>jp</sup>, <sup>jq</sup>, <sup>jr</sup>, <sup>js</sup>, <sup>jt</sup>, <sup>ju</sup>, <sup>jv</sup>, <sup>jw</sup>, <sup>jx</sup>, <sup>ja</sup>, <sup>jb</sup>, <sup>jc</sup>, <sup>jd</sup>, <sup>je</sup>, <sup>jf</sup>, <sup>jh</sup>, <sup>ji</sup>, <sup>jj</sup>, <sup>jk</sup>, <sup>jl</sup>, <sup>jm</sup>, <sup>jn</sup>, <sup>jo</sup>, <sup>jp</sup>, <sup>jq</sup>, <sup>jr</sup>, <sup>js</sup>, <sup>jt</sup>, <sup>ju</sup>, <sup>jv</sup>, <sup>jw</sup>, <sup>jx</sup>, <sup>ka</sup>, <sup>kb</sup>, <sup>kc</sup>, <sup>kd</sup>, <sup>ke</sup>, <sup>kf</sup>, <sup>kg</sup>, <sup>kh</sup>, <sup>ki</sup>, <sup>kj</sup>, <sup>kl</sup>, <sup>km</sup>, <sup>kn</sup>, <sup>ko</sup>, <sup>kp</sup>, <sup>kq</sup>, <sup>kr</sup>, <sup>ks</sup>, <sup>kt</sup>, <sup>ku</sup>, <sup>kv</sup>, <sup>kx</sup>, <sup>ky</sup>, <sup>kz</sup>, <sup>la</sup>, <sup>lb</sup>, <sup>lc</sup>, <sup>ld</sup>, <sup>le</sup>, <sup>lf</sup>, <sup>lg</sup>, <sup>lh</sup>, <sup>li</sup>, <sup>lj</sup>, <sup>lk</sup>, <sup>ll</sup>, <sup>lm</sup>, <sup>ln</sup>, <sup>lo</sup>, <sup>lp</sup>, <sup>lq</sup>, <sup>lr</sup>, <sup>ls</sup>, <sup>lt</sup>, <sup>lu</sup>, <sup>lv</sup>, <sup>lw</sup>, <sup>lx</sup>, <sup>ly</sup>, <sup>lz</sup>, <sup>ma</sup>, <sup>mb</sup>, <sup>mc</sup>, <sup>md</sup>, <sup>me</sup>, <sup>mf</sup>, <sup>mg</sup>, <sup>mh</sup>, <sup>mi</sup>, <sup>mj</sup>, <sup>mk</sup>, <sup>ml</sup>, <sup>mm</sup>, <sup>mn</sup>, <sup>mo</sup>, <sup>mp</sup>, <sup>mq</sup>, <sup>mr</sup>, <sup>ms</sup>, <sup>mt</sup>, <sup>mu</sup>, <sup>mv</sup>, <sup>mw</sup>, <sup>mx</sup>, <sup>my</sup>, <sup>mz</sup>, <sup>na</sup>, <sup>nb</sup>, <sup>nc</sup>, <sup>nd</sup>, <sup>ne</sup>, <sup>nf</sup>, <sup>ng</sup>, <sup>nh</sup>, <sup>ni</sup>, <sup>nj</sup>, <sup>nk</sup>, <sup>nl</sup>, <sup>nm</sup>, <sup>nn</sup>, <sup>no</sup>, <sup>np</sup>, <sup>nq</sup>, <sup>nr</sup>, <sup>ns</sup>, <sup>nt</sup>, <sup>nu</sup>, <sup>nv</sup>, <sup>nw</sup>, <sup>nx</sup>, <sup>ny</sup>, <sup>nz</sup>, <sup>oa</sup>, <sup>ob</sup>, <sup>oc</sup>, <sup>od</sup>, <sup>oe</sup>, <sup>of</sup>, <sup>og</sup>, <sup>oh</sup>, <sup>oi</sup>, <sup>oj</sup>, <sup>ok</sup>, <sup>ol</sup>, <sup>om</sup>, <sup>on</sup>, <sup>oo</sup>, <sup>op</sup>, <sup>oq</sup>, <sup>or</sup>, <sup>os</sup>, <sup>ot</sup>, <sup>ou</sup>, <sup>ov</sup>, <sup>ow</sup>, <sup>ox</sup>, <sup>oy</sup>, <sup>oz</sup>, <sup>pa</sup>, <sup>pb</sup>, <sup>pc</sup>, <sup>pd</sup>, <sup>pe</sup>, <sup>pf</sup>, <sup>pg</sup>, <sup>ph</sup>, <sup>pi</sup>, <sup>pj</sup>, <sup>pk</sup>, <sup>pl</sup>, <sup>pm</sup>, <sup>pn</sup>, <sup>po</sup>, <sup>pp</sup>, <sup>pq</sup>, <sup>pr</sup>, <sup>ps</sup>, <sup>pt</sup>, <sup>pu</sup>, <sup>pv</sup>, <sup>pw</sup>, <sup>px</sup>, <sup>py</sup>, <sup>pz</sup>, <sup>qa</sup>, <sup>qb</sup>, <sup>qc</sup>, <sup>qd</sup>, <sup>qe</sup>, <sup>qf</sup>, <sup>qg</sup>, <sup>qh</sup>, <sup>qi</sup>, <sup>qj</sup>, <sup>qk</sup>, <sup>ql</sup>, <sup>qm</sup>, <sup>qn</sup>, <sup>qo</sup>, <sup>qp</sup>, <sup>qq</sup>, <sup>qr</sup>, <sup>qs</sup>, <sup>qt</sup>, <sup>qu</sup>, <sup>qv</sup>, <sup>qw</sup>, <sup>qx</sup>, <sup>qy</sup>, <sup>qz</sup>, <sup>ra</sup>, <sup>rb</sup>, <sup>rc</sup>, <sup>rd</sup>, <sup>re</sup>, <sup>rf</sup>, <sup>rg</sup>, <sup>rh</sup>, <sup>ri</sup>, <sup>rj</sup>, <sup>rk</sup>, <sup>rl</sup>, <sup>rm</sup>, <sup>rn</sup>, <sup>ro</sup>, <sup>rp</sup>, <sup>rq</sup>, <sup>rr</sup>, <sup>rs</sup>, <sup>rt</sup>, <sup>ru</sup>, <sup>rv</sup>, <sup>rw</sup>, <sup>rx</sup>, <sup>ry</sup>, <sup>rz</sup>, <sup>sa</sup>, <sup>sb</sup>, <sup>sc</sup>, <sup>sd</sup>, <sup>se</sup>, <sup>sf</sup>, <sup>sg</sup>, <sup>sh</sup>, <sup>si</sup>, <sup>sj</sup>, <sup>sk</sup>, <sup>sl</sup>, <sup>sm</sup>, <sup>sn</sup>, <sup>so</sup>, <sup>sp</sup>, <sup>sq</sup>, <sup>sr</sup>, <sup>ss</sup>, <sup>st</sup>, <sup>su</sup>, <sup>sv</sup>, <sup>sw</sup>, <sup>sx</sup>, <sup>sy</sup>, <sup>sz</sup>, <sup>ta</sup>, <sup>tb</sup>, <sup>tc</sup>, <sup>td</sup>, <sup>te</sup>, <sup>tf</sup>, <sup>tg</sup>, <sup>th</sup>, <sup>ti</sup>, <sup>tj</sup>, <sup>tk</sup>, <sup>tl</sup>, <sup>tm</sup>, <sup>tn</sup>, <sup>to</sup>, <sup>tp</sup>, <sup>tq</sup>, <sup>tr</sup>, <sup>ts</sup>, <sup>tt</sup>, <sup>tu</sup>, <sup>tv</sup>, <sup>tw</sup>, <sup>tx</sup>, <sup>ty</sup>, <sup>tz</sup>, <sup>ua</sup>, <sup>ub</sup>, <sup>uc</sup>, <sup>ud</sup>, <sup>ue</sup>, <sup>uf</sup>, <sup>ug</sup>, <sup>uh</sup>, <sup>ui</sup>, <sup>uj</sup>, <sup>uk</sup>, <sup>ul</sup>, <sup>um</sup>, <sup>un</sup>, <sup>uo</sup>, <sup>up</sup>, <sup>uq</sup>, <sup>ur</sup>, <sup>us</sup>, <sup>ut</sup>, <sup>uu</sup>, <sup>uv</sup>, <sup>uw</sup>, <sup>ux</sup>, <sup>uy</sup>, <sup>uz</sup>, <sup>va</sup>, <sup>vb</sup>, <sup>vc</sup>, <sup>vd</sup>, <sup>ve</sup>, <sup>vf</sup>, <sup>vg</sup>, <sup>vh</sup>, <sup>vi</sup>, <sup>vj</sup>, <sup>vk</sup>, <sup>vl</sup>, <sup>vm</sup>, <sup>vn</sup>, <sup>vo</sup>, <sup>vp</sup>, <sup>vq</sup>, <sup>vr</sup>, <sup>vs</sup>, <sup>vt</sup>, <sup>vu</sup>, <sup>vv</sup>, <sup>vw</sup>, <sup>vx</sup>, <sup>vy</sup>, <sup>vz</sup>, <sup>wa</sup>, <sup>wb</sup>, <sup>wc</sup>, <sup>wd</sup>, <sup>we</sup>, <sup>wf</sup>, <sup>wg</sup>, <sup>wh</sup>, <sup>wi</sup>, <sup>wj</sup>, <sup>wk</sup>, <sup>wl</sup>, <sup>wm</sup>, <sup>wn</sup>, <sup>wo</sup>, <sup>wp</sup>, <sup>wq</sup>, <sup>wr</sup>, <sup>ws</sup>, <sup>wt</sup>, <sup>wu</sup>, <sup>wv</sup>, <sup>ww</sup>, <sup>wx</sup>, <sup>wy</sup>, <sup>wz</sup>, <sup>xa</sup>, <sup>xb</sup>, <sup>xc</sup>, <sup>xd</sup>, <sup>xe</sup>, <sup>xf</sup>, <sup>xg</sup>, <sup>xh</sup>, <sup>xi</sup>, <sup>xj</sup>, <sup>xk</sup>, <sup>xl</sup>, <sup>xm</sup>, <sup>xn</sup>, <sup>xo</sup>, <sup>xp</sup>, <sup>xq</sup>, <sup>xr</sup>, <sup>xs</sup>, <sup>xt</sup>, <sup>xu</sup>, <sup>xv</sup>, <sup>xw</sup>, <sup>xa</sup>, <sup>xb</sup>, <sup>xc</sup>, <sup>xd</sup>, <sup>xe</sup>, <sup>xf</sup>, <sup>xg</sup>, <sup>xh</sup>, <sup>xi</sup>, <sup>xj</sup>, <sup>xk</sup>, <sup>xl</sup>, <sup>xm</sup>, <sup>xn</sup>, <sup>xo</sup>, <sup>xp</sup>, <sup>xq</sup>, <sup>xr</sup>, <sup>xs</sup>, <sup>xt</sup>, <sup>xu</sup>, <sup>xv</sup>, <sup>xw</sup>, <sup>ya</sup>, <sup>yb</sup>, <sup>yc</sup>, <sup>yd</sup>, <sup>ye</sup>, <sup>yf</sup>, <sup>yg</sup>, <sup>yh</sup>, <sup>yi</sup>, <sup>yj</sup>, <sup>yk</sup>, <sup>yl</sup>, <sup>ym</sup>, <sup>yn</sup>, <sup>yo</sup>, <sup>yp</sup>, <sup>yq</sup>, <sup>yr</sup>, <sup>ys</sup>, <sup>yt</sup>, <sup>yu</sup>, <sup>yv</sup>, <sup>yw</sup>, <sup>ya</sup>, <sup>yb</sup>, <sup>yc</sup>, <sup>yd</sup>, <sup>ye</sup>, <sup>yf</sup>, <sup>yg</sup>, <sup>yh</sup>, <sup>yi</sup>, <sup>yj</sup>, <sup>yk</sup>, <sup>yl</sup>, <sup>ym</sup>, <sup>yn</sup>, <sup>yo</sup>, <sup>yp</sup>, <sup>yq</sup>, <sup>yr</sup>, <sup>ys</sup>, <sup>yt</sup>, <sup>yu</sup>, <sup>yv</sup>, <sup>yw</sup>, <sup>za</sup>, <sup>zb</sup>, <sup>zc</sup>, <sup>zd</sup>, <sup>ze</sup>, <sup>zf</sup>, <sup>zg</sup>, <sup>zh</sup>, <sup>zi</sup>, <sup>zj</sup>, <sup>zk</sup>, <sup>zl</sup>, <sup>zm</sup>, <sup>zn</sup>, <sup>zo</sup>, <sup>zp</sup>, <sup>zq</sup>, <sup>zr</sup>, <sup>zs</sup>, <sup>zt</sup>, <sup>zu</sup>, <sup>zv</sup>, <sup>zw</sup>, <sup>za</sup>, <sup>zb</sup>, <sup>zc</sup>, <sup>zd</sup>, <sup>ze</sup>, <sup>zf</sup>, <sup>zg</sup>, <sup>zh</sup>, <sup>zi</sup>, <sup>zj</sup>, <sup>zk</sup>, <sup>zl</sup>, <sup>zm</sup>, <sup>zn</sup>, <sup>zo</sup>, <sup>zp</sup>, <sup>zq</sup>, <sup>zr</sup>, <sup>zs</sup>, <sup>zt</sup>, <sup>zu</sup>, <sup>zv</sup>, <sup>zw</sup>.

TABLE 3

Binding constants ( $K_d$ , [nM]) of different CRF-related agonists and antagonists displacing [ $^{125}$ I-Tyr $^0$ ]oCRF from recombinant rCRFR1 or [ $^{125}$ I-Tyr $^0$ ]SvG from recombinant mCRFR2 $\beta$ .

No.	peptides	[ $^{125}$ I-Tyr $^0$ ]oCRF $K_d$ (rCRFR1), [nM]	[ $^{125}$ I-Tyr $^0$ ]SvG $K_d$ (mCRFR2 $\beta$ ), [nM]	Selectivity
1	oCRF	0.6 $\pm$ 0.1	162.4 $\pm$ 37.6	0.002
2	SvG	0.7 $\pm$ 0.1	4.5 $\pm$ 0.6	0.109
3	astressin <sup>a</sup>	5.7 $\pm$ 1.6	4.0 $\pm$ 2.3	1.00
11	[D <sup>1</sup> Phe <sup>11</sup> , His <sup>12</sup> ]SvG(11-40)	153.6 $\pm$ 33.5	1.4 $\pm$ 0.4	76.99
12	[D <sup>1</sup> Phe <sup>11</sup> ]SvG(11-40)	237.3 $\pm$ 27.7	3.5 $\pm$ 0.2	47.58
13	[D <sup>1</sup> Leu <sup>11</sup> ]SvG(11-40)	1670.0 $\pm$ 500.0	20.9 $\pm$ 4.1	56.07
14	SvG(11-40)	831.2 $\pm$ 668.8	15.4 $\pm$ 2.5	37.88
15	ATB-[Ala <sup>32</sup> ]astressin <sup>b,c</sup>	5.3 $\pm$ 1.3	2.6 $\pm$ 1.0	1.43
16	ATB-[Tyr <sup>32</sup> ]astressin <sup>d</sup>	20.4 $\pm$ 4.6	38.2 $\pm$ 7.2	0.37
17	ATB-[His <sup>12</sup> ]SvG(12-40)	142.5 $\pm$ 22.3	3.1 $\pm$ 0.2	32.26
18	[Tyr <sup>11</sup> , His <sup>12</sup> ]SvG(11-40)	220.9 $\pm$ 89.1	4.9 $\pm$ 1.8	31.64
19	[Tyr <sup>11</sup> ]SvG(11-40)	977.2 $\pm$ 551.0	20.8 $\pm$ 1.6	32.97
20	[Tyr <sup>12</sup> ]SvG(12-40)	995.5 $\pm$ 336.8	428.5 $\pm$ 118.9	1.63

<sup>a</sup>, astressin = cyclo(30-33)[Nle<sup>21,38</sup>, Glu<sup>30</sup>, Lys<sup>33</sup>]h/rCRF(12-41). <sup>b</sup>, ATB = 4-(1-azi-2,2,2-trifluoroethyl)benzoyl. <sup>c</sup>, [Ala<sup>32</sup>]astressin = cyclo(30-33)[Nle<sup>21,38</sup>, Glu<sup>30</sup>, Ala<sup>32</sup>, Lys<sup>33</sup>]h/rCRF(12-41). <sup>d</sup>, [Tyr<sup>32</sup>]astressin = cyclo(30-33)[Nle<sup>21,38</sup>, Glu<sup>30</sup>, Tyr<sup>32</sup>, Lys<sup>33</sup>]h/rCRF(12-41).

Selectivity was calculated according to the equation: Selectivity =  $K_d$ (rCRFR1) (agonist/antagonist)/ $K_d$ (mCRFR1) (astressin)  $\times$   $K_d$ (mCRFR2 $\beta$ ) (astressin)/ $K_d$ (mCRFR2 $\beta$ ) (agonist/antagonist).

TABLE 4

Potency of 1  $\mu$ M CRF antagonist to stimulate cAMP production in transfected HEK 293 cells (rel. IA, relative intrinsic activity). Efficacy of 1  $\mu$ M (rCRFR1) or 10 nM (mCRFR2 $\beta$ ) CRF antagonist to inhibit cAMP production stimulated by  $\alpha$ CRF (rCRFR1) or Svg (mCRFR2 $\beta$ ) (1 nM) in transfected HEK 293 cells (rel. pot., relative potency).

No.	peptides	HEK-rCRFR1 cells		HEK-mCRFR2 $\beta$ cells	
		rel. IA	rel. pot.	rel. IA	rel. pot.
1	$\alpha$ CRF	1.00	1.00	1.00	1.00
2	Svg	-	-	-	-
3	astressin	0.10 $\pm$ 0.02	0.11 $\pm$ 0.03	0.004 $\pm$ 0.001	0.57 $\pm$ 0.04
11	[DPhe <sup>11</sup> , His <sup>12</sup> ]Svg(11-40)	0.04 $\pm$ 0.01	0.73 $\pm$ 0.07	0.004 $\pm$ 0.001	0.42 $\pm$ 0.02
12	[DPhe <sup>11</sup> ]Svg(11-40)	0.07 $\pm$ 0.01	0.75 $\pm$ 0.13	0.005 $\pm$ 0.001	0.71 $\pm$ 0.04
13	[DLeu <sup>11</sup> ]Svg(11-40)	0.22 $\pm$ 0.04	0.92 $\pm$ 0.16	0.008 $\pm$ 0.002	0.75 $\pm$ 0.06
14	Svg(11-40)	0.14 $\pm$ 0.02	0.76 $\pm$ 0.16	0.005 $\pm$ 0.001	0.76 $\pm$ 0.02
15	ATB-[Ala <sup>32</sup> ]astressin <sup>b,c</sup>	0.10 $\pm$ 0.01	0.11 $\pm$ 0.05	0.010 $\pm$ 0.001	0.30 $\pm$ 0.05
16	ATB-[Tyr <sup>32</sup> ]astressin <sup>d</sup>	0.08 $\pm$ 0.01	0.49 $\pm$ 0.16	0.008 $\pm$ 0.003	0.68 $\pm$ 0.17
17	ATB-[His <sup>12</sup> ]Svg(12-40)	0.15 $\pm$ 0.01	0.54 $\pm$ 0.06	0.007 $\pm$ 0.002	0.48 $\pm$ 0.04
18	[Tyr <sup>11</sup> , His <sup>12</sup> ]Svg(11-40)	0.03 $\pm$ 0.01	0.79 $\pm$ 0.07	0.008 $\pm$ 0.002	0.37 $\pm$ 0.05
19	[Tyr <sup>11</sup> ]Svg(11-40)	0.09 $\pm$ 0.01	0.82 $\pm$ 0.06	0.007 $\pm$ 0.002	0.67 $\pm$ 0.04
20	[Tyr <sup>12</sup> ]Svg(12-40)	0.06 $\pm$ 0.03	0.90 $\pm$ 0.02	0.006 $\pm$ 0.002	0.60 $\pm$ 0.04
	basal	0.01 $\pm$ 0.003		0.004 $\pm$ 0.001	

<sup>a</sup>, astressin = cyclo(30-33)[Nle<sup>21,38</sup>, Gln<sup>30</sup>, Lys<sup>33</sup>]h/rCRF(12-41). <sup>b</sup>, ATB = 4-(1-azi-2,2,2-trifluoroethyl)benzoyl. <sup>c</sup>, [Ala<sup>32</sup>]astressin = cyclo(30-33)[Nle<sup>21,38</sup>, Gln<sup>30</sup>, Ala<sup>32</sup>, Lys<sup>33</sup>]h/rCRF(12-41). <sup>d</sup>, [Tyr<sup>32</sup>]astressin = cyclo(30-33)[Nle<sup>21,38</sup>, Gln<sup>30</sup>, Tyr<sup>32</sup>, Lys<sup>33</sup>]h/rCRF(12-41).



TABLE 5  
Physicochemical data of the CRF-analogs.

No.	peptides	RPHPLC <sup>a</sup>	R <sub>t</sub> [min] <sup>b</sup>	MS (average) calcd/found <sup>c</sup>
1	oCRF	99	25.9	4671.4/4669.2
2	Svg	99	25.4	4600.4/4599.4
3	astressin	99	24.8	3564.2/3563.3
4	α-helical CRF(9-41)	97	26.1	3827.4/3826.0
5	[DPhe <sup>12</sup> , His <sup>21,38</sup> ] <sub>12</sub> -CRF(12-41)	92	24.4	3540.2/3539.1
6	[DPhe <sup>12</sup> ]oCRF(12-41)	89	23.0	3490.1/3487.6
7	[DPhe <sup>11</sup> ]rUcn(11-40)	99	24.5	3641.2/3640.8
8	[DPhe <sup>11</sup> , Glu <sup>12</sup> ]rUcn(11-40)	99	25.3	3633.2/3629.9
9	[DLeu <sup>11</sup> , Glu <sup>12</sup> ]rUcn(11-40)	94	25.1	3599.1/3596.4
10	cyclo(29-32)[DPhe <sup>11</sup> , Glu <sup>29</sup> , Lys <sup>32</sup> ] rUcn(11-40)	99	24.7	3596.1/3593.2
11	[DPhe <sup>11</sup> , His <sup>12</sup> ]Svg(11-40)	97	21.6	3652.3/3650.3
12	[DPhe <sup>11</sup> ]Svg(11-40)	96	22.1	3644.3/3642.4
13	[DLeu <sup>11</sup> ]Svg(11-40)	98	22.9	3610.3/3608.5
14	Svg(11-40)	99	22.0	3610.3/3608.5

<sup>a</sup>, Percent purity determined by RPHPLC using solvent system: A = 0.1% TFA in water, B = 80% MeCN in 0.1% TFA in water. <sup>b</sup>, The retention time (R<sub>t</sub>) of the compounds was determined by RPHPLC. Samples were eluted with 5% B for 5 min and then with a linear gradient of 5-95% B in 30 min. <sup>c</sup>, The observed *m/z* of the average compared with the calculated [M+H]<sup>+</sup> average mass.

### References

1. Spiess, J., J. Rivier, C. Rivier, and W. Vale, *Proc. Natl. Acad. Sci. USA* **78**:6517-6521 (1981).
2. Vale, W., J. Spiess, C. Rivier, and J. Rivier, *Science* **213**:1394-1397, 1981
3. Vita, N., P. Laurent, S. Lefort, P. Chalon, J.-M. Lelias, M. Kaghad, G. Le Fur, D. Caput, and P. Ferrara, *FEBS Lett.* **335**:1-5, 1993
4. Chen, R., K. A. Lewis, M. H. Perrin, and W. Vale, *Proc. Natl. Acad. Sci. USA* **90**:8967-8971, 1993
5. Perrin, M. H., C. J. Donaldson, R. Chen, K. A. Lewis, and W. Vale, *Endocrinology* **133**:3058-3061, 1993
6. Chang, C.-P., R. V. Pearce II, S. O'Connell, and M. G. Rosenfeld, *Neuron* **11**:1187-1195, 1993
7. Yu, J., L. Y. Xie, and A. B. Abou-Samra, *Endocrinology* **137**:192-197, 1996
8. Dautzenberg, F. M., K. Dietrich, M. R. Palchaudhuri, and J. Spiess, *J. Neurochem.* **69**:1640-1649, 1997
9. Lovenberg, T. W., C. W. Liaw, D. E. Grigoriadis, W. Clevenger, D. T. Chalmers, E. B. De Souza, and T. Oltersdorf, *Proc. Natl. Acad. Sci. USA* **92**:836-840, 1995
10. Perrin, M., C. Donaldson, R. Chen, A. Blount, T. Berggren, L. Bilezikjian, P. Sawchenko, and W. Vale, *Proc. Natl. Acad. Sci. USA* **92**:2969-2973, 1995
11. Kishimoto, T., R. V. Pearce II, C. R. Lin, and M. G. Rosenfeld, *Proc. Natl. Acad. Sci. USA* **92**:1108-1112, 1995
12. Stenzel, P., R. Kesterson, W. Yeung, R. D. Cone, M. B. Rittenberg, and M. P. Stenzel-Poore, *Mol. Endocrinol.* **9**:637-645, 1995
13. Valdenaire, O., T. Giler, V. Breu, J. Gottowik, and G. Kilpatrick, *Biochim. Biophys. Acta* **1352**: 129-132, 1997
14. Vaughan, J., C. Donaldson, J. Bittencourt, M. H. Perrin, K. Lewis, S. Sutton, R. Chan, A. V. Turnbull, D. Lovejoy, C. Rivier, J. Rivier, P. E. Sawchenko, and W. Vale, *Nature (London)* **378**:287-292, 1995
15. Behan, D. P., S. C. Heinrichs, J. C. Troncoso, X. J. Liu, C. H. Kavas, N. Ling, and E. B. De Souza, *Nature (London)* **378**:284-287, 1995

16. Rivier, J., C. Rivier, R. Galyean, A. Miranda, C. Miller, A. G. Craig, G. Yamamoto, M. Brown, and W. Vale, *J. Med. Chem.* **36**:2851-2859, 1993
17. Hernandez, J. F., W. Kornreich, C. Rivier, A. Miranda, G. Yamamoto, J. Andrews, Y. Tache, W. Vale, and J. Rivier, *J. Med. Chem.* **36**:2860-2867, 1993
18. Miranda, A., S. C. Koerber, J. Gulyas, S. L. Lahrchi, A. G. Craig, A. Corrigan, A. Hagler, C. Rivier, and J. Rivier, *J. Med. Chem.* **37**:1450-1459, 1994
19. Gulyas, J., C. Rivier, M. Perrin, S. C. Koerber, S. Sutton, A. Corrigan, S. L. Lahrchi, A. G. Craig, W. Vale, and J. Rivier, *Proc. Natl. Acad. Sci. USA* **92**:10575-10579, 1995
20. Miranda, A., S. L. Lahrchi, J. Gulyas, S. C. Koerber, A. G. Craig, A. Corrigan, C. Rivier, W. Vale, and J. Rivier, *J. Med. Chem.* **40**:3657-3658, 1997
21. Chen, C., R. Dagnino Jr., E. B. De Souza, D. E. Grigoriades, C. Q. Huang, Kjung-Il Kim, Z. Liu, T. Moran, T. R. Webb, J. P. Whitten, Y. F. Xie, and J. R. McCarthy, *J. Med. Chem.* **39**: 4358-4360, 1996
22. Schulz, D. W., R. S. Mansbach, J. Sprouse, J. P. Braselton, J. Collins, M. Corman, A. Dunaïskis, S. Faraci, A. W. Schmidt, T. Seeger, P. Seymour, F. D. Tingley III, E. N. Winston, Y. L. Chen, and J. Heym, *Proc. Natl. Acad. Sci. USA* **93**:10477-10482, 1996
23. Christos, T. E., and A. Arvanitis, *Expert Opinion On Therapeutic Patents* **8**: 143-152, 1998
24. Baram, T. Z., D. T. Chalmers, C. Chen, Y. Koutsoukos, and E. B. De Souza, *Brain Research* **770**: 89-95, 1997
25. Lundkvist, J., Z. Chai, R. Teheranian, H. Hasanvan, T. Bartfai, F. Jenck, U. Widmer, and J.-L. Moreau, *Eur. J. Pharmacol.* **309**: 195-200, 1996
26. Fisher, L., C. Rivier, J. Rivier, and M. Brown, *Endocrinology* **129**:1312-1316, 1991
27. Donaldson, C. J., S. W. Sutton, M. H. Perrin, A. Z. Corrigan, K. A. Lewis, J. E. Rivier, J. M. Vaughan, and W. W. Vale, *Endocrinology* **137**:2167-2170, 1996
28. Gottowik, J., V. Goetschy, S. Henriot, E. Kitas, B. Fluhman, R. G. Clerc, J. L. Moreau, F. J. Monsma, and G. J. Kilpatrick, *Neuropharmacol.* **36**:1439-1446, 1997
29. Rühmann, A., A. K. E. Köpke, F. M. Dautzenberg, and J. Spiess, *Proc. Natl. Acad. Sci. USA* **93**:10609-10613, 1996
30. Grigoriadis, D. E., X.-J. Liu, J. Vaughn, S. F. Palmer, C. D. True, W. W. Vale, N.

Ling, and E. B. De Souza, *Mol. Pharmacol.* **50**:679-686, 1996

31. Liaw, C.W., D. E. Grigoriadis, M. T. Lorang, E. B. De Souza, and R. A. Maki,  
*Mol Endocrin* **11**:2048-2053, 1997

Claims

1. An antagonist of the ligand of the Corticotropin-Releasing Factor Receptor, type 2 (CRFR2) lacking the 8 to 10 N-terminal amino acids of native sauvagine.
2. The antagonist of claim 1 lacking the 10 N-terminal amino acids of native sauvagine.
3. The antagonist of claim 2 comprising the amino acid sequence Xaa<sub>1</sub>-Xaa<sub>2</sub>-Leu-Leu-Arg-Lys-Met-Ile-Glu-Ile-Glu-Lys-Gln-Glu-Lys-Glu-Lys-Gln-Gln-Ala-Ala-Asn-Asn-Arg-Leu-Leu-Leu-Asp-Thr-Ile-NH<sub>2</sub>, wherein Xaa<sub>1</sub> is a neutral amino acid, and Xaa<sub>2</sub> is a charged amino acid.
4. The antagonist of claim 3, wherein Xaa<sub>1</sub> is a hydrophobic amino acid, and Xaa<sub>2</sub> is Glu or His.
5. The antagonist of claim 4, wherein Xaa<sub>1</sub> is Leu.
6. The antagonist of claim 3, wherein Xaa<sub>1</sub> is a polar amino acid, and Xaa<sub>2</sub> is Glu or His.
7. The antagonist of claim 6, wherein Xaa<sub>1</sub> is Tyr.
8. The antagonist of any one of claims 3, 4 or 6, wherein Xaa<sub>1</sub> is in the D-configuration.
9. The antagonist of claim 8, wherein Xaa<sub>1</sub> is D-Leu.
10. The antagonist of claim 8, wherein Xaa<sub>1</sub> is D-Tyr.
11. The antagonist of any one of claim 5, 7, 9 or 10, wherein Xaa<sub>2</sub> is Glu.

12. The antagonist of claim 8, wherein Xaa<sub>1</sub> is D-Phe.
13. The antagonist of any one of claims 7, 10 or 12, wherein Xaa<sub>2</sub> is His.
14. An antagonist of the ligand of the Corticotropin-Releasing Factor Receptor, type 2 (CRFR2) lacking the 11 N-terminal amino acid of native sauvagine, wherein the N-terminal amino acid of said antagonist is a charged amino acid.
15. The antagonist of claim 14, wherein said charged amino acid is positively charged.
16. The antagonist of claim 15, wherein said charged amino acid is His.
17. The antagonist of any one of claims 14 to 16 which comprises a phenyldiazirine group coupled to the N-terminal amino acid of said antagonist.
18. The antagonist of claim 17, wherein said phenyldiazirine group is a 4-(1-aziridinyl)-2,2,2-trifluoroethylbenzoyl (ATB)-group.
19. A polynucleotide encoding the antagonist of any one of claims 1 to 7, 11, 13 or 14 to 16.
20. A vector comprising the polynucleotide of claim 19.
21. The vector of claim 20, wherein said polynucleotide is operatively linked to an expression control sequence.
22. A host comprising the polynucleotide of claim 19 or vector of claim 20 or 21.
23. A method for producing the antagonist of any one of claims 1 to 7, 11, 13, or 14 to 16, said method comprising culturing the host of claim 22 under conditions that cause the synthesis of said antagonist, and recovering said antagonist from the culture.

24. An antagonist obtainable by the method of claim 23.
25. An antibody directed against the antagonist of any one of claims 1 to 18, or 24.
26. An anti-idiotypic antibody directed against the antibody of claim 25.
27. A pharmaceutical composition comprising the antagonist of any one of claims 1 to 18, or 24, the polynucleotide of claim 19, the vector of claim 20 or 21, the antibody of claim 25 and/or the anti-idiotypic antibody of claim 26 and optionally a pharmaceutically acceptable carrier and/or diluent.
28. A diagnostic composition comprising the antagonist of any one of claims 1 to 18, or 24, the polynucleotide of claim 19, the vector of claim 20 or 21, the antibody of claim 25 and/or the anti-idiotypic antibody of claim 26.
29. A kit comprising
  - (a) an antagonist of any one of claims 1 to 18, or 24;
  - (b) the polynucleotide of claim 19;
  - (c) the vector of claim 20 or 21;
  - (d) the antibody of claim 25; and/or
  - (e) the anti-idiotypic antibody of claim 26.
30. Use of the antagonist of any one of claims 1 to 18, or 24, the polynucleotide of claim 19, the vector of claim 20 or 21, the antibody of claim 25 and/or the anti-idiotypic antibody of claim 26 for the preparation of a pharmaceutical composition for preventing and/or treating a Corticotropin-Releasing Factor Receptor, type 2 (CRFR2)-associated disease.
31. The antagonist of any one of claims 1 to 18, or 24, or the use of claim 30, wherein said CRFR2 is CRFR2 $\alpha$  or CRFR2 $\beta$ .
32. The use of claim 30 or 31 for preventing and/or treating affective disorders,

gastric intestinal diseases, cardiopathic diseases, psychiatric diseases, preferably eating disorders, anxiety disorders or anorexia nervosa, and/or Alzheimer's disease.


33. Use of the antagonist of any one of claims 1 to 18, or 24, the polynucleotide of claim 19, the vector of claim 20 or 21, the antibody of claim 25 and/or the anti-idiotypic antibody of claim 26 for the investigation of CRF receptor type-specific functions.



Abstract

The present invention relates to an antagonist of the ligand of the Corticotropin-Releasing Factor Receptor, type 2 (CRFR2) lacking the 8 to 10 N-terminal amino acids of native sauvagine. The present invention also relates to an antagonist of the ligand of the Corticotropin-Releasing Factor Receptor, type 2 (CRFR2) lacking the 11 N-terminal amino acids of native sauvagine, wherein the N-terminal amino acid of said antagonist is a charged amino acid. Furthermore, the present invention relates to a polynucleotide encoding the antagonist of the present invention, a vector comprising the polynucleotide of the present invention, and a host comprising the polynucleotide or the vector of the present invention. Also described are a method for producing the antagonist of the present invention, antibodies directed against the antagonist of the present invention, as well as anti-idiotypic antibodies directed against the antibody of the present invention. The present invention also relates to pharmaceutical and diagnostic compositions comprising the antagonist, the polynucleotide, the vector, the antibody, and/or the anti-idiotypic antibody of the present invention. Furthermore, the present invention relates to a kit comprising one or more of the above mentioned compounds of the present invention and to the use of one or more of these compounds for the preparation of a pharmaceutical composition for preventing and/or treating a Corticotropin-Releasing Factor Receptor, type 2 (CRFR2)-associated disease.

1/4



% = pyroglutamic acid  
f = D-phenylalanine  
B = norleucine  
L = lactam bridged  
■ = NH<sub>2</sub>

Fig. 1

2/4




Fig. 2

3/4




Fig. 3

4/4




Fig. 4